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Summary 
 
Leprosy is a bacterial disease of the skin and the nerves, caused by Mycobacterium 
leprae. Ever since the introduction of a multi-drug therapy in the 1970’s, worldwide 
incidence has been decreasing and the disease has been eradicated in many 
countries. However, in recent years occurrence of new cases remains stable at around 
200,000 per year. Most new cases are reported in developing countries, and India 
accounts for more than half of new cases registered every year. In my thesis, I 
investigated how innate immunity plays an important role in regulating the disease 
outcome during multi-drug-therapy. This is addressed by examining the transcriptome 
profile of specific cells of the innate immunity, namely the Natural Killer (NK) cells. 
Secondly, I investigated innate immunity-associated genes of the human host that are 
believed to play a significant role in regulating the disease outcome. The thesis is 
structured into four different chapters. 
In chapter I of my thesis, published as an original study, I evaluated four specific 
functional variants in three different genes that are part of the NOD-2 signaling 
pathway: NOD2 (rs9302752A/G), LRRK2 (rs1873613A/G), and RIPK2 (rs40457A/G 
and rs42490G/A). I utilized 211 clinically classified Indian leprosy patients with 230 
ethnically matched controls. The genetic variants were chosen for their role in innate 
immunity and because they had been found to be associated to leprosy in an earlier 
study carried out in a Han Chinese population. The LRRK2 locus proved to be 
associated with leprosy outcome. The LRRK2 rs1873613A minor allele and respective 
rs1873613AA genotype were significantly associated with an increased risk whereas 
the LRRK2 rs1873613G major allele and rs1873613GG genotypes conferred 
protection. Also, the reconstructed GA haplotype from the RIPK2 rs40457A/G and 
rs42490G/A variants was observed to contribute towards increased risk. 
In chapter II, also published as an original study, I investigated loci in the heterodimeric 
transporter associated with antigen processing (TAP) gene, which is known to play a 
vital role in immune surveillance. Functional variants both in TAP1 (rs1057141 
Iso333Val and rs1135216 Asp637Gly) and TAP2 (rs2228396 Ala565Thr and rs241447 
Ala665Thr) were genotyped using a study group of clinically classified Indian leprosy 
patients (n = 222) and ethnically matched controls (n = 223). The minor allele of TAP1 
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(637G) contributed to an increased risk of leprosy. In the dominant model, two of the 
researched genotypes of TAP1, rs1135216AG and rs1135216GG, contributed to an 
increased risk of leprosy as well. 
In the unpublished chapter III of my thesis, I investigated the interactions of M. leprae 
antigen with monocytes and monocyte-derived macrophages by fluorescence-
activated cell sorting. M. leprae whole cell antigen up-regulated L-Selectin expression 
in monocytes by 20%. This is a strong indicator of increased migration of phagocytic 
cells into the tissue upon identification of a threat by Mycobacterium leprae. 
Additionally, the CD163 expression is increased by 30% in macrophages. As CD163 
is an indicator of M2-macrophage activity this underlines the role of possible immuno-
evasion by the pathogen through alternative activation of macrophages. 
In chapter IV, also unpublished, peripheral blood mononuclear cells were extracted 
from fresh blood of 9 Indian leprosy patients (5 paucibacillary and 4 multibacillary) and 
three healthy, ethnically matched controls. The cells were then incubated and 
afterwards mRNA was isolated from them. The Natural Killer-cell transcriptome profile 
was investigated using microarray technology. LCN2 and APOBEC3 transcription was 
predominantly up-regulated in paucibacillary cases, while multibacillary cases were 
mostly unchanged and controls were down-regulated. A comparison of paucibacillary 
and multibacillary patients with controls as a baseline revealed that multibacillary 
patients generally showed a higher transcription of genes associated to cell-cell-
communication, a phenomenon not repeated in paucibacillary patients, which actually 
presented a down-regulation in comparison with healthy controls. Further, 
multibacillary patients also showed an up-regulation in gene-products involved in 
immunity. However, some notable exceptions emerged, such as CD70 and TNFRSF9. 
In conclusion, utilizing a combination of molecular genetics, cell-culture experiments, 
and microarray technology, a number of promising findings can be presented here 
which could serve in deepening our understanding of host-bacterial interactions in 
leprosy. 
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Zusammenfassung 
 
Lepra ist eine bakterielle Erkrankung der Haut und Nerven, die von Mycobacterium 
leprae hervorgerufen wird. Seit Einführung einer Antibiotikatherapie in den siebziger 
Jahren ist die Anzahl an weltweit Infizierten stark gesunken und die Krankheit ist in 
vielen Ländern ausgerottet. In letzter Zeit verbleibt die Zahl an registrierten 
Neuerkrankungen jedoch konstant bei ca. 200.000 Personen pro Jahr. Von den 
Ländern, die noch immer unter der Lepra leiden, verzeichnet Indien mehr als die Hälfte 
der jährlichen Neuerkrankungen. Die Erforschung der Besonderheiten im Genom der 
indischen Bevölkerung, die dieses ermöglichen, sowie die generelle Untersuchung der 
komplizierten Interaktionen zwischen Erreger und Wirtsimmunität sind die Ziele der 
hier präsentierten Ergebnisse. 
In den Studien für Kapitel I verglichen wir 211 klinisch klassifizierte indische 
Leprapatienten mit 230 ethnisch entsprechenden Kontrollen. Die vier untersuchten 
genetischen Varianten waren: NOD2 (rs9302752A/G), LRRK2 (rs1873613A/G), und 
RIPK2 (rs40457A/G und rs42490G/A). Ihnen wurde bereits eine Assoziation mit Lepra 
in einer früheren Studie mit Han Chinesen nachgewiesen. Das rezessive Allel LRRK2 
rs1873613A und der entsprechende Genotyp rs1873613AA waren signifikant mit einer 
erhöhten Infektionsgefahr assoziiert. Andererseits vermittelten das dominante Allel 
LRRK2 rs1873613G und der entsprechende Genotyp rs1873613GG in unserer 
Patientenkohorte einen Schutz gegen Lepra im Allgemeinen und gegen die 
pauzibazilläre Ausprägung im Besonderen. Zudem beobachteten wir, dass der GA 
Haplotyp der RIPK2 rs40457A/G und rs42490G/A Varianten mit einem erhöhten Risiko 
der Erkrankung einherging, während der AA Haplotyp einen Schutz vermittelte. 
Im Kapitel II wurden die möglichen Assoziationen von Polymorphismen in den Genen 
TAP1 und TAP2 zur Lepra in einer Kohorte von 222 klinisch klassifizierten indischen 
Leprapatienten untersucht und mit den Genotypen in 223 ethnisch entsprechen 
Kontrollen verglichen. Die Genotypisierung fand durch Sequenzierung in vier Loci statt: 
TAP1 (rs1057141 Iso333Val und rs1135216 Asp637Gly) und TAP2 (rs2228396 
Ala565Thr und rs241447 Ala665Thr). Das rezessive Allel TAP1 637G trug zu einer 
erhöhten Anfälligkeit für Lepra bei. Im dominanten Model trug der Genotyp TAP1 
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rs1135216AG + GG zusätzlich zu einer Erhöhung der Erkrankungswahrscheinlichkeit 
bei. 
Im Kapitel III wurden periphere mononukleäre Blutzellen verwendet, um die 
Interaktion von M. leprae-Antigen mit Monozyten und mit aus Monozyten gewonnenen 
Makrophagen via „fluorescence-associated cell sorting“ zu untersuchen. Wir fanden 
heraus, dass das verwendete Antigen die L-Selectin Expression in Monozyten um 20% 
erhöhte. Hier zeigt sich ein möglicher Hinweis darauf, dass die Migration von 
phagozytischen Zellen ins Gewebe von der Bedrohung durch Mycobacterium leprae  
gefördert wird. Zudem war die CD163 Expression in aktivierten Makrophagen um 30% 
höher. CD163 ist ein Indikator für M2-Makrophagenaktivität, daher ergeben sich aus 
dieser Tatsache weiterführende Fragestellungen über die Rolle von M. leprae in der 
alternativen Aktivierung von Makrophagen. Da alle Experimente mit einem Antigen 
ausgeführt wurden, das aus fragmentierten Bakterienzellen besteht, kann davon 
ausgegangen werden, dass die beobachteten Effekte passiver Natur sind. 
Für Kapitel IV wurden periphere mononukleäre Blutzellen von 9 indischen 
Leprapatienten (5 pauzibazillär und 4 multibazillär) und 3 ethnisch entsprechenden 
Kontrollen extrahiert. Die gewonnenen Zellen wurden inkubiert und anschließend 
deren mRNA isoliert. Hierüber wurde die genetische Aktivität durch Verwendung von 
„microarray“ Technologie bestimmt. Ein individueller Vergleich von Patienten und 
Kontrollen zeigte auf, dass LCN2 und APOBEC3 hauptsächlich in pauzibazillären 
Fällen hochreguliert wurden. Ein Vergleich der Patientengruppen enthüllte zudem, 
dass multibazilläre Patienten im Allgemeinen eine höhere Transkription von Genen 
zeigten, die mit interzellulärer Kommunikation assoziiert sind, wohingegen 
pauzibazilläre Patienten hier herunter regulierten. Außerdem präsentierten 
multibazilläre Patienten erhöhte Transkription von Genen, die in die Immunität 
involviert sind. Hier waren jedoch ein paar bemerkenswerte Ausnahmen festzustellen, 
wie zum Beispiel in den Fällen von CD70 und TNFRSF9. 
Abschließend lässt sich feststellen, dass diese Dissertation innovative Wege 
präsentiert, mit denen Lepra trotz der mit der Krankheit assoziierten Einschränkungen 
untersucht werden kann. Unter Verwendung einer Kombination von Methoden der 
molekularen Genetik, Zellkulturexperimenten, und „microarray“ Technologie war es 
uns möglich diverse interessante Entdeckungen zu machen, auf denen zukünftige 
Experimente fußen können. 
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General Introduction and Background 
1. Leprosy 
Leprosy, also known as Hansen’s disease, is a chronic infectious disease of the skin 
and nerves caused by the intracellular pathogenic bacterium Mycobacterium leprae.  
1.1 History 
The disease was first described by the Norwegian physician Gerhard Armauer Hansen 
in 1873, thus making it the first disease directly contributed to a bacterial causative 
agent. However, it is very clear that leprosy has been a long-lasting companion for 
humankind, with the oldest traces in medical texts reaching back all the way to 600 BC 
[1], though molecular analysis suggests that M. leprae has been a human pathogen 
long before the advent of medical documentation [2]. Until the 1970s, when a working 
antibiotic therapy was introduced, the disease was a long-standing companion of 
human societies specifically in the tropical and sub-tropical regions. Yet, despite 
decreased prevalence in the last four decades, the number of new case detection rates 
remains moderate to high in 130 countries worldwide [3] (Fig. 1). 
 
Figure 1: Leprosy prevalence rates as reported to WHO as of January 2012. Source: 
http://www.who.int/lep/situation/Leprosy_PR_2011.pdf 
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1.2 Distribution 
Amongst the countries still suffering from leprosy, India contributes to half of the new 
cases detected worldwide, with 120,000-130,000 new cases every year. India 
surpasses the second-ranking Brazil by four-fold (approximately 30,000 new cases per 
year) and third-ranking Indonesia by six-fold (approximately 20,000 new cases per 
year) [4]. 
The incidence in India has remained constant over the last five years despite an 
effective multi drug therapy regimen, consisting of a combination of rifampicin, 
clofazimin, and dapsone, being available and distributed [5]. It can be assumed that 
this fact is partially due to a multitude of specific host-pathogen interactions, as it has 
been shown that host immune responses [2, 6] and host genetic factors influence the 
clinical spectrum of leprosy [7-10]. In addition, a massive gene-loss event contributed 
to a greatly diminished genetic diversity of M. leprae [2, 11]. Taken together, the 
documented influence of host immune response on disease presentation and the low 
species diversity of the pathogen hint that host genetics may play a large role in 
disease outcome and persistence. This could also be a possible explanation for 
documented relapse during and/or shortly after treatment [12-14]. These listed facts 
allow for the conclusion that the spectral nature of the disease is largely influenced by 
host genetics, possibly elucidating the extraordinary role the disease still holds on the 
Indian sub-continent. 
1.3 Disease presentation 
What makes it possible to describe the disease as “genetic” is its wide range of 
manifestations, presumably based on the genetic makeup of the host’s immune 
system. The disease can range from the relatively mild form of tuberculoid leprosy to 
the sometimes crippling lepromatous presentation [15]. The lepromatous side of the 
spectrum is classified into borderline lepromatous (BL) and lepromatous (LL) forms. 
Following WHO standards, this form is also classified as multibacillary (MB), based on 
the observed bacillary load in slit skin smears. The tuberculoid form, on the other hand, 
is separated into tuberculoid (TT) and borderline tuberculoid (BT) forms and is 
classified as paucibacillary (PB). This classification does not only represent the 
symptoms during a leprosy, but also directly correlates to the patient’s ability to mount 
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a successful immune answer, or their failure to do so. In multibacillary, or lepromatous, 
forms, the absence of Th1 responses leads to an increased bacterial load with a strong 
humoral immune response [7]. On the other hand, the paucibacillary, or tuberculoid, 
forms reveal an increased Th1 response with limited bacterial load. 
1.4 Mycobacterium leprae 
Mycobacterium leprae belongs to the Mycobacteriaceae family, in which we also find 
Mycobacterium tuberculosis. The descriptive unifying element for this family is the 
incorporation of mycolic acids into the hydrophobic and waxy cell membrane. The lack 
of an outer membrane classifies Mycobacteriaceae as a Gram-positive bacterium. 
However, their cell-membrane cannot retain the crystal violet stain commonly used to 
identify Gram-positive bacteria. The Gram-stain is therefore replaced by the so-called 
Ziehl-Neelsen-stain, which uses carbol fuchsin for the identification of acid-fast bacilli. 
M. leprae is a slow growing pathogen. Researching the bacteria is made particularly 
hard due to the fact that they cannot be cultured and the available animal models are 
restricted to the nine-banded armadillo [16] and the footpads of BALBc mice [17]. 
Within the human body, M. leprae is an intracellular pathogen that resides inside 
macrophages and Schwann-cells of the nervous system. Both cell-types are directly 
correlated to disease presentation, with infected macrophages being found in great 
numbers in the characteristic lesions, while the reduced activity of infected Schwann-
cells is directly correlated to decreased sensitivity in limbs of leprosy patients. The 
reduced activity of infected cells depends in great parts on the introduction of large 
quantities of low-density lipids (LDLs), the resulting droplets giving the afflicted 
macrophages and Schwann-cells a “foamy” appearance in microscopic observation. It 
has been speculated that this phenotype is induced by the pathogen, partially in order 
to reduce phagocytic potential in infected macrophages, but also for energy production 
through the glyoxylate-cycle [18]. Interestingly, this “foamy” phenotype can be found in 
other diseases as well, namely tuberculosis [19], Whipple’s disease [20] and even 
atherosclerosis [21]. It is therefore possible to speculate on a common genetic 
predilection in certain individuals that is differentially exploited in various diseases, 
supporting the cause for genetic analysis in the patients. 
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This hypothesis is supported by the previously mentioned fact that the M. leprae 
genome is massively impeded in its function, with approximately 40% of the genes 
inactivated to become pseudogenes [11]. It can be assumed that the host cell 
overtakes vital duties for the bacteria. This is underlined by the findings that the 
bacteria massively reprogram infected Schwann-cells into a stem cell-like phenotype 
[22]. Adding the knowledge about gene-decay in M. leprae to the fact that the 
bacterium only has a genome of 3.31 megabase pairs (Mb), it does not come as a 
surprise that clonal differences between bacterial isolates from various countries 
(namely India, Thailand, Brazil, and the USA) amount to a mere 200 base pairs (bp), 
or just 0.005% of the whole genetic information of the organism [2]. Based on this 
information about low clonal frequency and the low mutation rate in pseudogenes, it 
was calculated that the evolutionary shift from a free-living form to an intracellular 
parasite took place approximately 20 million years ago [23]. 
Tracing the clonal patterns of the bacteria found in various localities around the globe, 
it has been deduced that the most likely origin of the disease was located in Eastern 
Africa, from which it spread towards Europe and Asia, only reaching Western Africa 
and the Americas through European colonization [2, 24]. 
The high dependency on the human host explains why M. leprae has not yet been 
grown in culture. Even growing the bacteria in animal models is mostly restricted to the 
footpads of BALBc-mice and the nine-banded armadillo. The latter is also the only 
known case of a naturally occurring leprosy in an organism other than humans. 
However, multilocus typing of the M. leprae strains of the armadillo suggests a human 
origin of not more than a few hundred years ago [24], with the most probable source 
being early European settlers. Thus, and in this particular setting, leprosy may possibly 
be of zoonotic origin [25]. 
1.4.1 Mycobacterium lepromatosis 
M. lepromatosis is a recently discovered relative of M. leprae and can be predominantly 
found in Central America [26, 27], though a single case has previously been identified 
in Singapore [28] and Canada [29], respectively. A study compared six corresponding 
genes in M. lepromatosis and M. leprae and found a heterology of 7.4%, strongly 
indicating a new species [30]. 
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A difference between the two species can also be seen in disease representation. 
While classical leprosy exhibits the previously mentioned symptoms, M. lepromatosis 
induces disseminated leprosy, a severe disease presentation quite unique for Mexico. 
It has been present as “Lucio’s phenomenon” in the area for at least the last two 
centuries [26, 31]. 
2. Innate immunity 
The term “innate immunity” covers a wide array of immunological measures that, 
opposed to acquired immunity, work fast and without priming. The defense against 
intracellular threats, such as Mycobacterium leprae, falls within this topic. 
2.1 Genetics in leprosy 
Considering its importance in fighting off intracellular threats, it becomes clear that the 
innate immune system represents the first line of defense against M. leprae. Of 
particular importance in bacterial threats to the immune system are the pattern 
recognition receptors (PRRs), which recognize microbial motifs and mount an immune 
answer. Amongst these PRRs, the Toll-like receptors (TLRs) play a prominent role in 
recognising microbial cell surfaces outside of immune cells, while nucleotide 
oligomerization domain (NOD)-like receptors are localized in the cytosol and are 
invaluable for recognising intracellular pathogens [32]. 
A recent genome-wide study in Chinese leprosy patients has provided vital insights on 
the role of particularly NOD2 (rs9302752A/G), LRRK2 (rs1873613A/G) and RIPK2 
(rs40457A/G and rs42490G/A) variants in regulating the leprosy infection [10]. In 
addition, the expression of these genes has been shown to be up-regulated in the 
tissue of patients with leprosy when compared to healthy individuals [33]. The 
Nucleotide-binding oligomerization domain 2 (NOD2) is an intracellular microbial 
sensor for muramyl dipeptide, a component of bacterial peptidoglycan [34]. 
Dysregulation in NOD2 signalling is associated with pathogenesis in many 
inflammatory disorders [35] and is also associated with triggering of IL-32-dependent 
dendritic cell programing in leprosy [36]. It can therefore be summarized that NOD2 
plays an important role in leprosy [37, 38]. Additionally interesting in the context of 
Zhang et al.’s study [10] is the discovery that both NOD1 and NOD2 also activate the 
gene encoding receptor-interacting serine-threonine kinase 2 (RIPK2) [39]. 
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RIPK2 belongs to the group of kinases and is essential for signaling through the Toll-
like receptors, key regulators of the innate immune system [39, 40]. In addition, NF-κB 
activity is enhanced by interaction of RIPK2 with NOD2 [41], making it an important 
player in cellular immune response. 
The Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) belongs to the 
PARK family of genes. While LRRK2 is predominantly known for its interaction with 
parkin (PARK2) in Parkinson’s disease, both LRRK2 and PARK2 have been previously 
implicated of playing a role in leprosy [42-44]. In fact, the connection between 
Parkinson’s and leprosy goes so far that rifampicin, a staple drug in the multi-drug 
therapy (MDT) of leprosy, has been found to also be of use in treating Parkinson’s in 
an animal model [45]. LRRK2 also has been proven to be an important player in other 
inflammatory diseases [46] and in reaction to microbial threat [47, 48]. 
We investigated the possible association of gene variants in NOD2 (rs9302752A/G), 
LRRK2 (rs1873613A/G) and RIPK2 (rs40457A/G and rs42490G/A) with leprosy 
outcome in a cohort of clinically classified patients from India. 
As pointed out above, the decision whether to mount a cellular Th1 or a humoral Th2 
defense is a vital part in the fight of the immune system against M. leprae. Therefore it 
is important to observe the points in the immune answer where the switch between 
Th1- and Th2-response occurs. This statement is not only true in the specific case of 
leprosy, as observations here can, due to the high impact of host genetics on immunity 
in this disease, also be extrapolated to other diseases [49, 50]. The delivery of major 
histocompatibility complex (MHC) class I molecules from cytosol to the endoplasmic 
reticulum is the first step to mounting a Th2 response through antigen presentation on 
the cell surface. It is facilitated by the transporter associated with antigen processing 
(TAP), a heterodimer composed of two subunits TAP1 and TAP2. Polymorphisms in 
the TAP genes are already known to be associated with other inflammatory diseases, 
including autoimmune diseases such as rheumatoid arthritis, and in tuberculosis [51-
55]. 
The role of the TAP genes deserves a special focus in regards to the part they play in 
tuberculosis, as both the causative agent of this disease as well as leprosy belong to 
the same genus of Mycobacterium. Therefore we investigated TAP polymorphisms 
that were shown to be associated to tuberculosis: TAP1 rs1057141 (Iso333Val) and 
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rs1135216 (Asp637Gly), as well as TAP2 rs2228396 (Ala565Thr) and rs241447 
(Ala665Thr) [53, 54]. 
2.2 The shifting nature of macrophages 
In recent years the existence of a macrophage polymorphism that expresses a non-
classical phenotype has been discovered [56, 57]. Finally, it was found that 
macrophages can “polarize” into differently acting phenotypes upon activation through 
cytokine or Toll-like-receptor (TLR) stimulation [58]. Furthermore, these polarized 
macrophages can change their phenotype in response to growth factors (e.g. colony 
stimulating factor 1 (CSF-1) and granulocyte/macrophage colony stimulating factor 
(GM-CSF)) and other activating impulses, such as microbial threat, phagocytosis, or 
corticoids [59, 60]. 
Polarized macrophages are generally categorized into the classically activated M1, 
and the alternatively activated M2 phenotype [61, 62], replicating the Th1/Th2 
dichotomy. However, this separation is not as clear here as it is in T-helper cells.  
In general, the M1 phenotype can be differentiated by flow-cytometry through its strong 
surface expression of CD86 and CD80, which is quantitatively lower in the M2-
population [63] (Fig. 2). Further, the M1-phenotype strongly expresses IL-12 and IL-
23, while IL-10 production remains meagre. M1-macrophages produce effector 
molecules (reactive oxygen species and nitrogen intermediates) and inflammatory 
cytokines (IL-1ȕ, TNF, IL-6) and participate in Th1 responses [64, 65]. In this manner 
they help mediate resistances against intracellular pathogens. 
M2-macrophages present high levels of scavenger, mannose, and galactose-type 
receptors, particularly CD163 (scavenger receptor) and CD206 (mannose receptor) 
[66]. Unlike M1-macrophages, the M2 variant acts less directly within the immune 
system and overtakes a role more akin to a regulating and clean-up force. The cells 
take part in parasite clearance [67], dampening of inflammation and the promotion of 
tissue remodelling thereafter [68, 69], as well as general immunoregulation. 
2.3 M2-Macrophages in tuberculosis 
As mentioned already, the scavenger receptor CD163 is a commonly accepted marker 
for general M2-macrophage-activity, particularly in tissue-repair after inflammatory 
challenge. CD163 is characteristically up-regulated by the anti-inflammatory cytokine 
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IL10 and, consequently, down-regulated by the pro-inflammatory TNF-α and IFN-γ 
[70]. 
 
Figure 2: The different parameters used to identify M1 macrophages and M2 macrophage-sub-types as 
proposed by Mantovani et al. [71]. 
It can be assumed, therefore, that the CD163 profile, in accordance with M2 activity, 
would generally be low during an infection and increase notably after, in order to 
participate in immuno-reconstitution measures. This is supported by findings 
concerning M. tuberculosis, where, in a macaque-model of tuberculosis, anti-
inflammatory macrophages carrying CD163 were only found in the periphery of 
granulomas, adjacent to uninvolved tissue, and never associated to a strong bacterial 
presence [72]. Further, in vitro studies of artificially with M. tuberculosis infected 
monocytes showed a notable reduction of CD163 on the cell surface only in 
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tuberculosis patients, while healthy controls appeared unaffected [73]. The expression 
of CD163 did not increase either for patients or healthy controls. 
In yet another study it was observed that immune-histochemical stains of tuberculous 
granuloma samples contained only a small percentage of cells that expressed CD163 
at all (21%) [74]. Interestingly, upon examination of samples from Schistosoma 
mansoni-induced granulomas, CD163 positive cells made up 73% per-cent of the 
samples. S. mansoni is known for its ability to modulate the immune answer, so this 
may have played a role here. 
As M. leprae is an organism that, to date, cannot be grown in vitro, a certain degree of 
conjecture in regards to its effects on the human immune system is necessary. The 
closely related M. tuberculosis serves as a good entry point for understanding M. 
leprae-activity within the human body, as not only do the two organisms share a 
common ancestor and still have approximately 1400 genes in common [23], they also 
behave similarly in situ [75-77]. Therefore, M2-activity during tuberculosis could 
present a good indicator for the same activity during leprosy, hinting at CD163 as a 
probable indicator for measuring M2-activity in human leprosy. 
For the reasons mentioned above we investigated macrophage-polarization in leprosy 
based on CD163 as a reliable marker. 
2.4 L-Selectin 
L-Selectin, or CD62L, is a part of the extravasation process of leukocytes, including 
monocytes, into the tissue [78, 79]. It acts as an anchor on the cells’ surface, tying 
them to the epithelium and allowing for the characteristic rolling movement that 
precedes the migration into the tissue. 
The lack of L-Selectin has been found to play a role in the formation of inflammation-
causing cardiovascular disease [80, 81]. This is of interest in mycobacterial infection, 
as a common macrophage-phenotype, which imports massive amounts of low-density 
lipids, can be found in both M. leprae and M. tuberculosis infections as well as in 
arteriosclerosis [18, 82]. Also, the diseases caused by those pathogens both involve 
inflammatory processes comparable to those found in arteriosclerosis [83-85]. L-
Selectin also plays an important role in the clearance of inflammation. This is proven 
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by the discovery that anti-CD62L antibodies inhibit the recruitment of monocytes and 
neutrophils to inflammatory sites [78]. 
Considering its important role in inflammatory processes in humans and particularly in 
the recruitment of monocytes into the tissue, we decided to observe the role of L-
Selectin in the particular case of leprosy. 
3. Natural killer cells 
Natural killer cells (NK-cells) are lymphoid cells of the innate immunity. They participate 
in the clearance of tumor cells [86] as well as the clearance of cells affected by 
intracellular parasites like viruses [87] and bacteria such as M. tuberculosis [88]. They 
are also a major source of the type 1 cytokine IFN-γ, as well as TNF-α, GM-CSF, and 
other cytokines and chemokines associated with type 1 immunity and inflammation 
[89, 90]. 
3.1 NK-cells and macrophages 
As both NK-cells and macrophages play important roles in innate immunity, their 
interaction bears importance in this context. Indeed, it has been found recently that 
NK-cell-derived interferon γ influences the above mentioned macrophage sub-
populations differently [91]. This influence also seems to vary in between the sexes 
[92]. However, it seems that the interaction between the two cell types is not entirely 
mutually beneficial, as a recent study revealed killing of macrophage sub-types M0 and 
M2, though not M1, through lysis by activated NK-cells [93]. The same study found that 
M1 macrophages showed increased resistance to lysis through their elevated HLA I 
surface expression. 
3.2 NK-cells and mycobacterial diseases 
As mycobacteria are intracellular pathogens, NK-cells play an important role in the 
body’s defense against them. They have been proven to heavily channel and edit 
dendritic cell (DC) activity in Mycobacterium tuberculosis-infected tissue, particularly 
granuloma [94-96]. NK-cells can induce DC-maturation and are often found to kill 
immature DCs in peripheral tissue. 
The above-mentioned interaction of NK-cells with phagocytic cells can also be found 
in the immune system’s fight against tuberculosis. In particular, NK-cell-activated 
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monocytes that have phagocytised M. tuberculosis show a mycobactericidal activity 
that is 84% greater than in control monocytes [97]. 
A great part of the NK-cells’ antimicrobial activity is conveyed through their ability to 
produce IFN-γ in great quantities. This was shown in an experiment with mice, where 
NK-cell-knockout or anti-IFN-γ individuals showed great susceptibility particularly to M. 
tuberculosis [98]. The role of IFN-γ especially in tuberculosis is underscored by its 
greatly diminished production in acute pulmonary tuberculosis and the rapid return to 
normal levels after successful treatment [99]. 
The activity of NK-cells in leprosy is less well researched than in tuberculosis. The 
main focus of studies over the recent years has been on the NK-produced cytokines 
and their activities. Thus it was found, for example, that interleukins (IL) 12 and 18 
induce host-cell death in a murine leprosy model [100]. Further studies revealed that 
IL13 has a modulatory effect on the activity initiated by IL18, possibly by affecting IFN-
γ production by NK-cells [101]. 
Perhaps unsurprisingly, the human leukocyte antigen (HLA) surface marker plays a 
dominant role in the interaction of NK-cells with cells hosting M. leprae [102, 103], 
informing NK cells of the host cell status and initiating intervention. Even more so, 
certain HLA genotypes elicit a protective effect against leprosy [104, 105]. Also of note: 
The killer immunoglobulin-like receptor (KIR) family is engaged in the recognition of 
host cells as well and it has been proven that certain genotypes are more beneficial for 
avoiding persisting infection [106]. 
Based on results stemming from the investigation of tuberculosis as well as the known 
role of NK-cells in innate immunity, particularly against leprosy, we decided to 
investigate the transcriptome-level activity of NK cells in leprosy patients utilizing 
microarray technology. 
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Objectives 
Innate immunity is of the utmost importance in defending the human body against 
leprosy. The studies presented in this thesis aim at describing the host-pathogen 
relationship in the context of innate immunity from a molecular/cell biology point of view 
in the hope of expanding the scope of future research into treatment of the disease. 
Our research is focused on the Indian population, as the Indian sub-continent 
contributes more than half of all newly diagnosed leprosy cases worldwide each year. 
 
Specific Objectives 
 
1. The significance of single nucleotide polymorphisms in the NOD2, LRRK2, 
and RIPK2 genes, which have been proven to be associated with leprosy in 
past studies, was investigated using a case control study design in an Indian 
population. 
2. The significance of leprosy-associated single nucleotide polymorphisms in 
the immune surveillance-relevant genes TAP1 and TAP2 was investigated 
in a case control study design. 
3. The influence of Mycobacterium leprae antigens on monocyte recruitment 
and macrophage activation was investigated. 
4. Natural Killer cells are extremely important in defending against intra-cellular 
pathogens. The NK cell transcriptome profile in leprosy patients was 
therefore compared to healthy, ethnically matched controls. 
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Results 
Chapter I 
LRRK2 and RIPK2 Variants in the NOD2-Mediated Signaling Pathway Are 
Associated with Susceptibility to Mycobacterium leprae in Indian Populations 
(published) 
The observed genotype and allele frequencies of all studied SNPs in clinically 
classified patient groups and controls were in Hardy-Weinberg equilibrium (P > 0.05) 
except for the NOD2 SNP rs9302752 (P < 0.05). Therefore the NOD2 SNP rs9302752 
was excluded from further association analysis. 
We observed that the minor allele LRRK2 rs1873613A and the homozygous genotype 
rs1873613AA were more frequent in leprosy patients than in controls, with odds ratios 
that imply an increased risk for the development of leprosy (OR = 1.7, 95% CI = 1.25–
2.2, P = 0.0003 and OR = 2.04, 95% CI = 1.2–3.6, P = 0.007, respectively). The major 
allele LRRK2 rs1873613G and the homozygous genotype rs1873613GG were 
observed less frequently in patients compared to controls implicating a decreased risk 
of leprosy (OR = 0.61, 95% CI = 0.45–0.8, P = 0.0003 and OR = 0.56, 95% CI = 0.37–
0.83, P = 0.0028, respectively). When only clinically classified paucibacillary (PB) 
patients were compared to controls, a similar trend was observed with a stronger 
significance (for the minor allele rs1873613A: OR = 2.77, 95% CI = 1.9–4.1, P < 
0.0001; for the homozygous genotype rs1873613AA: OR = 4.1, 95% CI = 2.1–7.9, P 
< 0.0001). There was no significant association between the multibacillary (MB) 
presentation of the disease and this genotype. 
In the observed leprosy patients both the studied RIPK2 variants (rs40457A/G and 
rs42490G/A) were found to be in a high degree of linkage disequilibrium (LD, Leprosy 
patients: D’= 0.64, LOD = 12.72, r2 = 0.2; MB patients: D’ = 0.53, LOD = 5.84, r2 = 0.56; 
PB patients: D’= 0.84, LOD = 7.58, r2 = 0.34). In controls we only found a low degree 
(D’= 0.38, LOD = 3.2, r2 = 0.06). Four haplotypes and their frequencies were observed: 
AG, AA, GA and GG. The RIPK2 haplotype GA was observed more frequently in 
leprosy patients compared to healthy controls, inferring an increased risk of leprosy 
(OR = 1.46, 95% CI = 1.02–2.1, P = 0.036), whereas RIPK2 haplotype AA was 
observed less frequently in leprosy patients compared to controls, inferring a protection 
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against leprosy (OR = 0.69, 95% CI = 0.49–0.97, P = 0.028). In addition, RIPK2 
haplotype GA was observed more frequently in PB patients in comparison to controls, 
inferring an increased risk of this particular presentation of the disease (OR = 1.8, 95% 
CI = 1.1–2.8, P = 0.018). Furthermore, there was no significant difference of RIPK2 
haplotype frequencies in comparison between MB patients and controls. This is 
notable in the context of Zhang et al.’s genome-wide association study [10], which 
found the SNP rs42490 in the RIPK2 gene to have a stronger association towards the 
MB presentation of leprosy. 
Chapter II 
Genetic evidence of TAP1 gene variant as a susceptibility factor in Indian leprosy 
patients (published) 
Two of the observed loci (one in TAP1 rs1057141 and one in TAP2 rs241447) were 
not in Hardy–Weinberg equilibrium. These were excluded from further analysis and 
haplotype analysis was not attempted. 
The TAP1 rs1135216 (Asp637Gly) in exon 10 was observed to be a susceptibility 
factor. The presence of the minor allele of this locus (rs1135216G) was observed to 
be significantly higher in patients than in healthy control individuals (OR: 1.68, 95% CI 
1.2–2.36, P= 0.0057). The susceptibility was comparable in both the paucibacillary 
(PB) and the multibacillary (MB) patient cohorts. 
Similar observations were made in the dominant genetic model (AA) for this variant 
when comparing patients with controls or clinically classified patient groups with 
controls: Patients vs. Controls (OR: 2.01, 95% CI 1.34–3.03, P= 0.0012); MB vs. 
Controls (OR: 1.92, 95% CI 1.21–3.03, P= 0.011); PB vs. Controls (OR: 2.20, 95% CI 
1.25–3.90, P= 0.015). The recessive model (GG) did not produce any statistically 
significant associations. 
For the TAP2 SNP rs2228396 (Asp637Gly) in exon 10 we did not observe any 
significant contributions (after p-value corrections) either between patients and controls 
or between clinically classified patient groups compared to controls. 
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Chapter III 
Interaction of Mycobacterium leprae with human monocytes increases L-
Selectin expression and influences phagocytosis (not published) 
After six days of incubation, CD14+ cells (at this point macrophages) showed an 
increase in internal complexity and size in FACS. Only approximately 4.5% of them 
were still CD62L+ when compared to CD14+ cells on day zero (at this time point they 
were still monocytes). When monocytes were only incubated for 3 days and then 
stimulated with Mycobacterium leprae whole cell sonicate (WCS) overnight, CD62L-
expression across individuals increased by 30%, indicating that transformation into 
macrophages had not fully occurred yet. 
After incubation with WCS for 18 hours, matured macrophages showed a significantly 
different phenotype when compared to non-activated macrophages. Both size and 
internal complexity, represented by the FSC and SSC values respectively, changed 
upon stimulation. Upon activation with WCS, macrophages showed an up-regulation 
of CD163 that was more than 20% higher than that of non-stimulated controls. 
Chapter IV 
Transcriptome profile of natural killer cells in patients treated with multi-drug-
therapy (not published) 
When comparing expression profiles of the patients (NK 2, 4-6, 8, and 11-12) with each 
other and with the healthy controls (NKK) we found three groups emerging: NK2 and 
NK11 are both member of the paucibacillary (PB) group, while NK4 and NK6 both are 
multibacillary (MB) patients. NKK1 and NKK3 both belong to the control group. It is 
notable that we found a number of outliers that could not be included in any of the 
mentioned groups based on their expression, even including one of the controls. All of 
the outliers were excluded from further analysis. 
Comparing patients and controls on an individual level, we found a number of genes 
up-regulated in infected individuals when compared to healthy controls (NKK samples). 
Of particular prominence were the genes for lipocalin 2 (LCN2) and apolipoprotein B 
mRNA editing enzyme catalytic polypeptide 3 (APOBEC3), which both were more 
differentially expressed in multibacillary patients than in paucibacillary ones. 
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We also found a number of Y- and X-chromosomal genes differentially expressed, 
such as protein kinase, Y-linked (PRKY) and kelch-like 4 (KLHL4). They were 
adequately expressed in different genders, with PRKY, for example, being only up-
regulated in males. This serves as an additional quality control for the microarray data. 
When the multibacillary and the paucibacillary patients were compared with the values 
from the control group as a baseline, we found two distinct clusters where PB and MB 
patients differed greatly and genetic activity was diametrically opposed, i.e. up-
regulated in the PB group and down-regulated in the MB group and vice versa. 
The first cluster is dominated by gene-products that play a role in immunity (CD70, 
phospholipase A2, group IVC (cytosolic, calcium-independent) [PLA2G4C], and tumor 
necrosis factor receptor superfamily, member 9 [TNFRSF9]). These genes were more 
strongly expressed in PB patients. 
The second, larger cluster on the other hand includes many molecules involved in 
general cell-cell-communication, like signal-regulatory protein gamma (SIRPG), or pro-
platelet basic protein (chemokine (C-X-C motif) ligand 7) (PPBP). The genes in this 
cluster were more strongly expressed in MB patients. 
 
 
 
 
 
 
 
 
 
25 
 
General discussion 
The Indian population is highly represented in the global annual new case registration 
rate of leprosy. Investigating the variations in immunity-associated genes in Indian 
patient populations should help to find specific susceptibility loci that regulate disease 
outcome in general and in the Indian setting in particular. 
Research of leprosy is further complicated by the inability to grow M. leprae in culture. 
Even animal models fail for the most part, as outlined in the introduction. Taken 
together, these facts underline the need for experiments built around cell cultures and 
isolated patient samples. 
The studies described in this work are an attempt to perform a two-pronged analysis 
of the immune system of the leprosy patient, utilizing molecular as well as cell culture 
methods, thus circumventing the particular problems mentioned above. 
1. Immunogenetics 
Individual and ethnical immunogenetics play a greater role in leprosy than in most other 
diseases, as the causative agent, Mycobacterium leprae, presents such little genetic 
drift. Any variations in disease progression observed can therefore be traced back 
directly to the host’s genetic make-up. 
1.1 Chapter I 
The results outlined in chapter I are useful for pointing out the influence of population 
differences in regards to leprosy. 
We investigated genetic variants in NOD2 (rs9302752A/G), LRRK2 (rs1873613A/G) 
and RIPK2 (rs40457A/G and rs42490G/A). These positions were derived from a whole 
genome association study of leprosy patients in a Han-Chinese population by Zhang 
et al. [10]. The three genes NOD2, LRRK2, and RIPK2 are interlocked in a tightly-knit 
gene-interaction network (see Fig. 3). 
While our study population doesn’t compare to Zhang et al.’s study in size (211 patients 
in our study versus 706), we found our locus frequencies to be in accordance with both 
the Chinese study and the Gujarati Indian population found within the HapMap project 
(http://hapmap.ncbi.nlm.nih.gov/). It can be assumed that observed differences are 
based on differences in the populations rather than on differences in sample sizes. 
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Figure 3: Gene-interaction network including NOD2, LRRK2, and RIPK2 by Zhang et al. [10]. Highlighted genes 
have been proven to be associated to susceptibility towards leprosy. 
The Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) plays an 
extremely important role in the immune-defense, particularly against the threat of 
intracellular pathogens [107]. Through recognition of peptidoglycan it initiates detection 
of intracellular bacteria and commences autophagy, pro-inflammatory pathways, and 
other means of host-defense. Finding genetic variations of this particular gene would 
open up intriguing lines of questioning its efficiency in the fight against intracellular 
pathogens such as M. leprae. 
The researched NOD2 locus, rs9302752A/G, was not within Hardy-Weinberg-
Equilibrium, despite the minor allele frequency in our study being found to be 
comparable to the one identified by Zhang et al. (0.28 and 0.22 respectively). The fact 
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that we did not find an independent population for this locus is probably based on 
longstanding Indian marital traditions vis-à-vis the caste system [108]. We attempted 
to counter this known effect of population stratification by recruiting a great variety of 
patients and ethnically matched controls within the metropolis region of Hyderabad, 
Telangana, hoping that an urban mixture of study participants would result in a non-
stratified study group. We achieved this goal with the remaining three loci, but we had 
to exclude locus rs9302752A/G from further analysis. 
The major allele of the single nucleotide polymorphism rs1873613A/G of the gene 
LRRK2 was found with a similar frequency in our study group as reported in Gujarati 
Indians in Houston, Texas (GIH) in the HapMap project (0.68 and 0.61 respectively). 
LRRK2 and its gene-product Leucine-rich repeat kinase 2 are predominantly known 
for their involvement in the occurrence of Parkinson’s disease (PD) [109]. PD is a 
degenerative affliction of the central nervous system, caused primarily by the as-of-yet 
poorly understood death of cells in the substantia nigra area of the mid-brain. Recent 
studies have discovered involvement of the gene in inflammatory priming in monocytes 
[110] and in autophagy [111], both of which help to establish the degenerative 
phenotype of PD. LRRK2 has also been implicated in Crohn’s disease (CD) [112], an 
inflammatory bowel disease. Known polymorphisms promoting development of CD 
have also been proven to play a role in leprosy patients in Vietnam [113]. 
The influence of LRRK2 in pathologies that involve inflammation and autophagy make 
it a prime candidate for research in leprosy, as both processes feature prominently in 
leprotic morbidity and in the M. leprae infectious process respectively [114-116]. We 
found in our study disease-association of the major allele G, as did Zhang et al. Within 
our population, we also found the very same polymorphism to be particularly 
associated to the paucibacillary spectrum of the disease, a result that wasn’t replicated 
in the Han Chinese population researched by Zhang et al. Here, on the other hand, the 
polymorphism rs1491938C/T was found to be associated to the multibacillary spectrum 
of the disease exclusively. 
The variation between the Han Chinese and the Indian population in regards to the 
observed LRRK2 polymorphism rs1873613A/G is not surprising, considering the 
already mentioned great dependency of the pathogen on the genetic makeup of a 
population. Therefore it is possible to have, within considerable close proximity in 
Central to Southern Asia, three different ethnicities which present three different effects 
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of the polymorphism on disease progression: While in a Vietnamese population 
rs1873613A/G does not play a statistically significant role [113], in our Indian 
population the major allele is directly associated to the disease, even to a particular 
representation (paucibacillary). And in a Han Chinese population we find a general 
association, but it is an entirely different polymorphism in the gene, rs1491938C/T, 
which influences disease representation (towards multibacillary) [10]. 
Our results regarding LRRK2, when put in a context of similar studies covering different 
ethnicities, demonstrate how ethnic variability can influence leprosy outcome. 
RIPK2 was investigated at the positions rs40457A/G and rs42490G/A. This gene 
encodes receptor-interacting serine/threonine-protein kinase 2. The enzyme is of great 
importance in innate inflammatory pathways [117-119]. It has also been proven to be 
involved in various inflammatory morbidities, such as inflammatory bowel disease 
[120], Crohn’s disease [113, 118], sarcoidosis [121], or inflammatory arthritis [122]. 
The initial discovery by Zhang et al. of RIPK2 playing a role in leprosy in a Han-Chinese 
population was re-established by the same group through independent experiments 
involving a gene-expression study [33] as well as a gene-polymorphism association 
study involving only the rs40457A/G locus [123]. 
In this context of established results regarding leprosy and the overall involvement of 
RIPK2 in various inflammatory disorders we decided to include the two loci identified 
in Zhang et al.’s whole genome association study in our experiments. However, within 
our Indian population we did not find any association of the single polymorphisms 
towards either presentation of the disease. We assume that this is partially due to 
sample size, as even in the study by Zhang et al., including 706 patients and 1225 
controls, the discovered p-values for the loci were, considering the sample sizes, 
moderately significant, with rs42490G/A at p-value = 1.23*10-3 and rs40457A/G at p-
value = 1.43*10-2. Still, we are certain that part of the lack of association is due to the 
already discussed great variation of ethnic genetic differences. 
This line of thought is corroborated by findings in a Vietnamese population, where in 
474 patients only the rs42490G/A locus, and not the rs40457A/G counterpart, was 
found to be significantly associated to leprosy, with a p-value of just 0.043 [113]. Our 
own results within an Indian population show an association to leprosy only when 
observing the haplotypes of the RIPK2 loci. The combination of major allele A in 
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rs40457 and minor allele A in rs42490 exhibited a moderate association with a p-value 
of 0.028. The odds ratio found was 0.69, indicating an association of this haplotype 
towards protection against the disease. When examining the combination of minor 
allele G in rs40457 and minor allele A in rs42490 we achieved a moderate association 
of 0.036. However, in this case the odds ratio was found to be 1.46, conveying a 
tendency towards disease progression. 
Taken together the results of the haplotype analysis of the RIPK2 gene imply that major 
allele A in rs40457 conveys a protective effect against leprosy in the Indian population, 
while minor allele G in this locus supports disease progression. Minor allele A in 
rs42490 exaggerates the respective effect to a degree that makes the association 
visible even in a smaller population such as ours. This is in agreement with Zhang et 
al.’s findings both in the whole genome association study and in the context of a RIPK2-
NOD2 interaction study [123] where rs40457 was found to be associated with disease 
protection. In the Vietnamese study rs42490G/A alone was associated to disease 
progression, with an odds ratio of 1.2 [113]. Additionally, it appears that the 
combination of rs40457G and rs42490A particularly supports disease progression 
towards the paucibacillary spectrum, as we found a significant p-value of 0.018 and an 
odds ratio of 1.8 when examining the haplotypes in the context of the paucibacillary 
sub-population within our study. 
In conclusion it can be stated that the results of chapter I particularly point out the great 
value of re-examining results of immunogenetics studies of leprosy in various ethnic 
contexts, as even geographically close populations can show varying and sometimes 
even opposing results. It is of utmost importance to be mindful of the differences in 
genetic make-up of the various ethnic populations under threat by leprosy today when 
attempting to design new treatments attempting new drug regimes. 
1.2 Chapter II 
Chapter II serves to highlight the similarities of the role of immunogenetics in the 
context of leprosy and tuberculosis. 
The transporter associated with antigen processing (TAP) is specialized in transporting 
cytosolic peptides to HLA class I molecules in the endoplasmic reticulum (ER) [124] 
(See Fig. 4). It consists of two subunits, TAP1 and TAP2, which belong to the ATP-
binding cassette family of transporter molecules. The transporter’s elevated 
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importance in the context of immunity can easily be proven by the fact that deletion or 
mutation of either one or both subunits severely reduces translocation of peptides to 
the ER, resulting in the so-called “TAP-deficiency syndrome” (TDS) [125]. Resulting 
clinical manifestations are, amongst others, recurrent bacterial infections of the upper 
respiratory tract within the first six years of life, progressing into infections of the lower 
respiratory tract by the second decade of life. Antiviral immunity does not seem to be 
affected. The most striking symptom of TDS in the context of leprosy is the occurrence 
of necrotizing granulomatous skin lesions, typically located on the extremities or in the 
mid-face. The lesions heal very slowly and often leave hyperpigmented scars behind. 
In their behavior and appearance they seem very close to the lesions found on many 
leprosy patients. 
 
Figure 4: The central role of the TAP-complex in the processing of antigen-peptides by Parcej et al. [126]. 
TAP has also long been known to be involved in various diseases, such as ankylosing 
spondylitis [51], a chronical inflammatory disease of the joints, vitiligo [127], HIV-
infection [128], or, in particular, tuberculosis [53, 129]. Based on Sunder et al.’s 
discovery of the involvement of TAP1-polymorphisms rs1057141A/G and 
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rs1135216A/G, as well as TAP2-polymorphisms rs2228396G/A and rs241447A/G, in 
tuberculosis-HIV-co-infection [53], we decided to investigate the influence of these 
polymorphisms in the context of leprosy. Furthermore, the population in their study was 
recruited from the same area as ours, i.e. the greater metropolitan area of Hyderabad, 
India. Our approach is additionally supported by findings that connect some of the very 
same polymorphisms described above to susceptibility towards both pulmonary 
tuberculosis and tuberculoid leprosy in a population in New Delhi, India [55]. 
The minor allele combination GG in TAP1 rs1057141A/G was found to be significantly 
associated with HIV-TB-co-infection when compared with controls (p-value = 0.01) and 
HIV-only individuals (p-value = 0.03) by Sunder et al. [53]. Also, the major allele 
combination AA was represented at a significantly lower concentration in the co-
infection group than in HIV-only individuals (p-value = 0.05), indicating protective 
activity at least against tuberculosis. In general, they found allele G to be positively 
associated to HIV-TB-co-infection, while allele A appeared to be negatively associated, 
conveying a certain degree of protection. We, on the other hand, could not find this 
SNP to be within Hardy-Weinberg-equilibrium and thus excluded it from further 
analysis. We assume that this fact is based on the size of the examined population, 
222 patients in our study versus 345 for Sunder et al. This assumption is supported by 
the low significance of the observations in the latter study, with p-values ranging from 
0.01 at best to 0.05. This should improve with sample size. 
 For the TAP1 polymorphism rs1135216A/G both Sunder et al. as well as our study 
found significances. In our study, we found the minor allele G to be highly positively 
associated to the disease in general. Examining the MB and PB sub-groups separately 
revealed less significant p-values for both. While association to the MB group was just 
barely significant with a p-value of 0.054, the association towards the PB group was 
moderately high, with a p-value of 0.013. Observing the results utilizing a dominant 
model (AA versus AG + GG) resulted in mostly the same, though general association 
towards the disease appeared stronger while association towards the MB group now 
was of a higher significance than that of the PB group. All of the above reveals that, 
while G is the minor allele at position rs1135216 in the Indian population, its effect on 
leprosy manifestation and disease outcome dominates that of the major allele A when 
present. 
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The findings of Sunder et al. support ours in some regards. They found the 
heterozygous genotype AG to be significant in the HIV-TB-co-infected individuals, 
particularly when compared to HIV-positive ones. This significant association can be 
traced back, as in our case, to the minor allele G, where they found a moderate 
association with a p-value of 0.03 when comparing HIV-TB-co-infected individuals with 
HIV-only controls. Of course, the genotype associations of a study involving HIV-TB-
co-infected individuals cannot be entirely equal to our findings in the context of leprosy. 
This would explain why Sunder et al. found a negative association of the AA genotype 
and HIV-TB-co-infection at this position, while we couldn’t identify a significant 
contribution of the major allele A at all. Still, identifying the same association for the G 
allele at this position for a study involving the same population, from the greater 
metropolitan area of Hyderabad, India, underscores the close relationship of 
tuberculosis and leprosy in regards to immunogenetics. 
Rajalingam et al. in their study involving patients with tuberculoid leprosy and 
pulmonary tuberculosis did not find any significant associations for the TAP1 
genotypes researched within our study [55]. Considering that their study populations 
consisted of 50 individuals with tuberculoid leprosy and 57 with pulmonary 
tuberculosis, this demonstrates the need for sufficient numbers of samples to identify 
the effect of the researched TAP1 genotypes. 
Despite the relatively small number of individuals enrolled into the study, Rajalingam 
et al. found significant associations of the researched TAP2 genotypes to both 
tuberculoid leprosy and pulmonary tuberculosis. These results couldn’t be repeated 
within either Sunder et al.’s or our study. For both studies, TAP2 rs2228396G/A 
revealed no significant associations. 
We could not find Hardy-Weinberg-equilibrium for the polymorphism rs241447A/G 
within our study population and thus did not calculate associations. Sunder et al. also 
did not establish a Hardy-Weinberg-equilibrium, yet still calculated associations. They 
found the AA genotype to be moderately associated with HIV-TB-co-infection. At the 
same time, the AG genotype was found to be associated with protection. Rajalingam 
et al. found the minor allele G to be generally associated with protection against 
pulmonary tuberculosis, mirroring the results of Sunder et al., while in the case of 
tuberculoid leprosy the minor allele conveyed disease susceptibility in a highly 
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significant manner. However, Rajalingam et al. did not test for Hardy-Weinberg-
equilibrium either. 
The studies by Sunder et al. and Rajalingam et al. in the context of our results lead to 
a variety of conclusions: While the results in Rajalingam et al. in regards to the TAP2 
polymorphisms are interesting and seemingly build a bridge between the 
immunogenetics of leprosy and tuberculosis, the small sample size and the neglect of 
establishing Hardy-Weinberg-equilibrium hampers the conclusions that can be drawn. 
On the other hand, Sunder et al.’s results in the context of HIV-TB-co-infection mirror 
very well our own results in the context of leprosy. As the study populations in both 
publications can be considered as generally the same, also studying the same 
polymorphisms, this leads to intriguing insights into the similarities of the 
immunogenetics of both leprosy and tuberculosis. Future research will have to take 
into account the possibility that discoveries regarding one of these two diseases may 
be able to translate into the research of the other, and vice versa. 
2. Cell culture experiments 
As Mycobacterium leprae cannot be grown in culture and the best available animal 
model, the nine-banded armadillo, necessitates extensive animal facilities, cell culture 
experiments are the tool of choice for elucidating direct impact of the bacteria on the 
immune system. We believe an activation via M. leprae whole cell sonicate (WCS) 
achieves a reaction of immune cells that is quite close to the one in situ. Our particular 
goals in this study were to identify the activation potential of monocytes and 
macrophages in vitro in the context of leprosy and to estimate the role of macrophage 
sub-populations in this setting. 
2.1 Chapter III 
CD62L, or L-Selectin, plays a major role in the leukocyte extravasation [79]. Of 
particular interest is its involvement in the migration of monocytes into inflamed tissue 
(Fig. 5). Here they mature into macrophages [130, 131], losing L-Selectin [132]. 
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Figure 5: The functional roles of L-Selectin in leukocyte recruitment and extravasation by Grailer et al. [133]. 
Due to its properties we chose L-Selectin as a marker of both maturation of monocytes 
into macrophages as well as monocyte activation. After three days of incubation, our 
cells showed a marked increase of L-Selectin expression by 30% on their surface when 
stimulated with WCS. On the one hand, this demonstrates that after three days, 
monocytes in culture do not turn into macrophages yet, as they still present a great 
quantity of L-Selectin. On the other hand, it can be assumed that the increase in L-
Selectin expression means that Mycobacterium leprae WCS has monocyte-migration 
inducing properties. The increase in L-Selectin could be a direct reaction to the 
presence of antigen and a first step to initiate tissue-migration. This theory is supported 
by findings in mice that showed monocytes with high L-Selectin-expression as the first 
responders to acute inflammation [134]. Further, studies in elderly patients with chronic 
inflammation found a trade-off between reduced L-Selectin-expression, and thus 
reduced migration of monocytes, and an increased susceptibility to acute infection 
[135, 136]. 
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In summary, this underlines the importance of L-Selectin in estimating the activation 
status of monocytes. It is important to note that our findings could also hint at an up-
regulation of monocyte migration as a survival strategy of M. leprae, as this would 
serve to increase the number of macrophages at the infection site. This would leave 
the bacteria with a greater population of host-cells to infect. 
After incubation for six days, a further examination for CD62L expression on the cell 
surface revealed a strong decrease. For the reasons stated above we considered this 
as a sign that monocyte maturation into macrophages had taken place. The newly 
matured monocyte-derived macrophages (MDMs) were incubated with M. leprae 
whole cell sonicate for eighteen hours. This resulted in changes of the internal plasticity 
as well as the surface expression of CD163. Changes of the internal plasticity of cells 
can be measured in fluorescence-associated cell sorting by observing the so-called 
side scatter (SSC). This measures the refraction of light on its way through the cell. 
The greater the amount of internal structures, the greater is the refraction, and 
therefore the measured SSC. In our case we found an increase of SSC in MDMs after 
treatment with whole cell sonicate when compared to untreated controls. The sonicate 
consists of broken up whole bacterial cells in a solution. It can be assumed that the 
observed increase in SSC is due to an increase in phagosomes as a result of 
phagocytosis of the bacterial debris by MDMs. CD163 is a well-known scavenger 
receptor that in recent years has been identified as an indicator for alternatively 
activated, i.e. M2, macrophages [71]. It has been documented as being strongly 
expressed in tissues of lepromatous leprosy patients [137, 138]. A recent study 
established an in vitro model for granuloma formation in leprosy, similar to the one 
utilized in our manuscript [139]. An up-regulation of CD163 after activation with live M. 
leprae bacilli occurred here as well. 
Moura et al. hypothesized that CD163 may function as an alternative route of entry for 
M. leprae and that the observed up-regulation under influence of the bacteria is a mean 
of supporting the infection via facilitating the entry into host cells [140]. They found 
significantly higher CD163-mRNA levels in lesions of lepromatous patients than in 
those of borderline tuberculoid ones. Further, 41.7% of macrophages isolated from 
lepromatous lesions were shown to be CD163-positive. This is more than our 21.1% 
increased CD163-expression in stimulated MDMs, but this may be due to the 
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differences of comparing isolated macrophages from patients and MDMs that were 
stimulated in vitro. 
The hypothesis that M. leprae utilizes CD163 to its own advantage is lent credence 
through comparison to the closely related M. tuberculosis. Here we find the expected 
decrease or stagnation in expression during active threat [70, 73]. These two species 
generally cause similar immune answers and morbidities, yet they show completely 
opposite effects on the polarization of macrophages. We conclude that it is possible 
that Mycobacterium leprae enhances Macrophage polarization towards M2 
populations in order to facilitate invasion via CD163. Mycobacterium tuberculosis, 
where this mode of invasion hasn’t been encountered yet, would have no need to 
influence immunity this way. 
Alternatively, as the literature clearly reveals a bias towards M2 polarization on the 
lepromatous side of the spectrum, it can be assumed that enhancing alternative activity 
in macrophages over classical, anti-pathogen activity provides an added benefit for the 
pathogen, as it hinders an effective immune answer. M2 macrophages, more 
associated to clean up after an infection is over, would be less effective at fighting a 
leprosy than their classically activated counterparts. 
The integral role of M2 polarization in sustaining an ongoing leprosy of the lepromatous 
type is made even clearer as a successful treatment causes a shift from the 
lepromatous towards the tuberculoid end of the disease spectrum which is 
accompanied by a shift from predominantly M2 macrophages towards a predominantly 
M1 population [137]. 
Finally, we can state that the influence of the bacteria on macrophage polarization is 
passive rather than active. This is shown by our own results, where the effect was 
caused by sonicated bacteria, as well as the literature, where often whole, but dead, 
bacteria are being used for in vitro experiments [140, 141]. It would be logical to 
assume that surface factors on the bacterial cells are influencing the shift in 
macrophage populations, as the effect can be seen with whole dead bacteria. 
In conclusion we can state that, even though our study population is too small to make 
statistically significant statements, it serves as an interesting proof of principle about 
the influence of Mycobacterium leprae on L-Selectin and macrophage polarization. 
Further studies will have to be conducted to support our theses. 
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3. Microarray of Natural Killer cells 
Cell culture experiments utilizing activating antigens are one way to research the 
interaction of Mycobacterium leprae with the human immune system. However, they 
are still only an approximation of the real events in situ and therefore have to be 
corroborated by additional methods that enable us to see what occurs from different 
perspectives. One method through which this might be achieved is the transcriptome 
analysis of immune cells in leprosy patients. 
We chose Natural Killer (NK) cells as our target as they occupy a very central role in 
cellular immunity, killing infected cells and interacting with macrophages in various 
ways (Fig. 6). 
 
Figure 6: The interaction of macrophages and Natural Killer cells by Fehniger et al. [142]. 
3.1 Chapter IV 
This chapter describes a study involving 9 patient samples and 3 healthy controls from 
the greater Hyderabad city area in India. As the numbers of individuals are 
comparatively low, any results achieved should be regarded as exploratory 
groundwork to build on for planning and executing future studies. Figure 7 shows the 
relationships in expression patterns in between samples in a dendrogram. 
Due to the small sample size we decided to discard outliers completely and only 
concentrate analysis on the groups NK2 + Nk11, NK4 + NK6, and the control group 
NKK1 + NKK3. The group involving NK12 and NKK2 was not included as it includes a 
patient and a control sample. This may be because samples were taken after 
completing a WHO-approved course of antibiotics, so immunity of individual NK12 
could have returned to pre-infection levels at this point. 
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NK2 and NK11 represent the paucibacillary patients, while NK4 and NK6 are both 
multibacillary. For the remainder of this text they will be referred to as the 
“paucibacillary” and the “multibacillary” group respectively. 
Comparing gene-expression of patients versus controls reveals a number of genes 
that are differentially expressed, the most prominent one being SPP1. This gene codes 
for secreted phosphoprotein 1, also known as osteopontin. The protein can act as a 
cytokine that up-regulates production of interferon gamma and interleukin 12, both 
great influences in type 1 immunity [143]. Up-regulation in the context of leprosy is 
therefore not surprising. 
We also found that LCN2 was differentially expressed. The gene product, lipocalin 2, 
has been implicated in anti-bacterial activity, acting as a siderophore [144, 145]. The 
expression is more pronounced in the paucibacillary than in the multibacillary group, 
implying a possible role in fighting off M. leprae by association to the patient group that 
generally manages the pathogen better. 
It is remarkable that APOBEC3-expression is almost the same as that of LCN2. The 
gene-product, apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3, has five 
sub-groups in humans (Ab, B, C, F, G). We couldn’t identify the sub-group. All 
APOBEC3 sub-groups are generally associated to retroviral defense [146, 147]. The 
Figure 7: Cluster dendrogram of leprosy patients and controls according to microarray data. 
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fact that we find very similar expression in both the anti-bacterial LCN2 and APOBEC3 
could hint at an as of now undescribed immunological activity by the latter. 
We also compared the paucibacillary with the multibacillary patient groups, utilizing 
expression in the control group as a baseline. As the number of individuals was small, 
we opted to only include genes in the analysis that had a fold-change of greater than 
log3 when compared to the expression in the control group. 
The gene which shows the greatest differences in fold-changes in the two groups is 
CD70, being strongly down-regulated in the multibacillary and slightly up-regulated in 
the paucibacillary group. The product of this gene belongs to the tumor necrosis factor 
(TNF) ligand family and is a ligand for CD27 on T-cells, where the CD70/CD27 
interaction is critical for the cell’s expansion and survival [148]. CD70 also enhances 
the direct cytotoxic activity of natural killer and T-cells [149, 150]. The negative fold-
change of -2.8 in multibacillary cases, which fail to mount an effective immune answer 
against the pathogen in leprosy, is of interest in this context. 
SIRPG (signal-regulatory protein gamma), with a slight up-regulation (0.9) in the 
multibacillary group and a strongly negative fold-change of -2.2 in the paucibacillary 
group, shows a mirror picture of CD70. The gene product of SIRPG is indicated in 
regulatory processes, especially with CD47 [151]. CD47 is a central player in, amongst 
other things, apoptosis and migration. 
Also strongly indicated in regulatory processes and up-regulated by a fold-change of 
2.1 in the paucibacillary cohort of our study is RMRP (RNA component of mitochondrial 
RNA processing endoribonuclease), which has been proven to play a role in cell growth 
and division [152]. 
PPBP (pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) is up-regulated 
0.6-fold in the multibacillary patients, compared with a down-regulation of -1.7 in the 
paucibacillary individuals. Derivatives of PBP (platelet basic protein), such as PPBP, 
have demonstrated an anti-microbial activity in monocytes [153]. PPBP also works as 
a chemo-attractant for neutrophils [154]. Considering its beneficial role in immunity, the 
fact that PPBP is down-regulated in paucibacillary individuals, which are considered 
as having a working immune answer against M. leprae, has to be investigated further. 
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Another gene whose transcription is down-regulated in the paucibacillary group is 
EMR4. The gene product is a member of the EGF-TM7 receptor gene family, though 
sequencing results indicate that it may be soluble instead of membrane-bound in 
humans [155]. It could be a possible mean of G-protein-mediated cellular signaling, a 
central part of signal-transmission in humans. 
In the same context as above, the down-regulation of the FPR1 gene product in the 
paucibacillary group becomes noteworthy. The negative fold-changes of EMR4 and 
FPR1 (-1.9 versus -1.8) are very similar, and FPR1 is a member of the G-protein 
coupled receptor family 1. FPR1 plays a role in natural killer cell-mediated cytolytic 
activity [156] and in anti-inflammatory activity [157]. 
KIR2DS3 is a member of the killer cell immunoglobulin-like receptor family and 
transfers activating signals into the Natural Killer cell. In our study it shows a positive 
fold-change of roughly 1.9 in the multibacillary group. The gene also plays a role in 
other pro-inflammatory diseases, such as hepatitis C [158]. Given this information, it 
appears that transfer of activating signals into natural killer cells works in multibacillary 
patients and therefore doesn’t represent a fault line that is exploited by the bacteria. 
Another gene of interest due to its importance in immunity is tumor necrosis factor 
receptor superfamily, member 9 (TNFRSF9). In our study, transcription was up-
regulated in paucibacillary patients and the gene product is known for part-taking in 
the recognition of antigen presenting cells by T- and B-lymphocytes [159]. It has also 
been implicated in increasing dengue virus-mediated apoptosis in vitro [160]. 
Conclusions 
The preceding chapters represent alternative ways to investigating the interplay of 
Mycobacterium leprae and human immunity in the context of leprosy, circumventing 
the lack of an in vitro model for the pathogen. They show that the bacteria both directly 
and indirectly influence the host’s immune answer and that particularly the Indian 
population presents very distinct immunogenetics that influence the progress of the 
disease and make it more receptive. 
The genetic association towards leprosy and its progression in the Indian population 
will have to be intensively studied so that we may understand why the disease proves 
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so particularly resilient here. Our results hint at a particular role of innate immunity in 
this context, giving a direction to future research endeavors. 
In vitro activation of immune cells via antigens and the careful investigation of patient 
samples allows us a window into host-pathogen interactions and will help us identifying 
novel ways to fighting off the disease. Here, again, innate immunity appears as a mayor 
player beyond its standard role as a defense mechanism, possibly taking over the role 
as a facilitator of leprosy. 
The results presented within this document are only step stones towards identifying 
how leprosy still persists to such a great degree on the Indian sub-continent, and we 
will have to further our research based on the results achieved towards more effective 
personal therapy of the individual and widespread eradication of leprosy. 
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Abstract
In recent years, genome wide association studies have discovered a large number of gene loci that play a functional role in
innate and adaptive immune pathways associated with leprosy susceptibility. The immunological control of intracellular
bacteria M. leprae is modulated by NOD2-mediated signaling of Th1 responses. In this study, we investigated 211 clinically
classified leprosy patients and 230 ethnically matched controls in Indian population by genotyping four variants in NOD2
(rs9302752A/G), LRRK2 (rs1873613A/G), RIPK2 (rs40457A/G and rs42490G/A). The LRRK2 locus is associated with leprosy
outcome. The LRRK2 rs1873613A minor allele and respective rs1873613AA genotypes were significantly associated with an
increased risk whereas the LRRK2 rs1873613G major allele and rs1873613GG genotypes confer protection in paucibacillary
and leprosy patients. The reconstructed GA haplotypes from RIPK2 rs40457A/G and rs42490G/A variants was observed to
contribute towards increased risk whereas haplotypes AA was observed to confer protective role. Our results indicate that a
possible shared mechanisms underlying the development of these two clinical forms of the disease as hypothesized. Our
findings confirm and validates the role of gene variants involved in NOD2-mediated signalling pathways that play a role in
immunological control of intracellular bacteria M. leprae.
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Introduction
Leprosy is a chronic infectious disease of the skin and nerves,
caused by the bacterium Mycobacterium leprae. Despite decreased
prevalence in last two decades, the number of new case detection
rates remains high as far as in 130 countries, with India
contributing to half of the new cases detected worldwide [1].
Host immune responses [2,3] and genetic factors had been shown
to influence the clinical spectrum of leprosy [4–7]. Most notable is
inter individual variability in disease development, with a wide
range of manifestations ranging from lepromatous to tuberculoid
leprosy [8]. The lepromatous leprosy is distinguished as borderline
lepromatous (BL) and lepromatous (LL) forms and is classified as
multibacillary (MB) based on the bacillary load, whereas the
tuberculoid leprosy is distinguished as tuberculoid (TT) and
borderline tuberculoid (BT) and are classified as paucibacillary
(PB) by WHO standards. A difference in immune responses
between multibacillary and paucibacillary forms are predicted. In
multibacillary or lepromatous forms, the absence of Th1 responses
increases the bacilli load with strong humoral immunity [4]. On
the other hand, the paucibacillary or the tuberculoid forms reveal
an increased Th1 response with limited bacterial load.
The intracellular M. leprae has an extended incubation period
for up to 30 years. The pathogen driven selection can
potentially alter the primed sequence and can direct to
substantial changes in gene expression [9]. The pathogen
recognition receptors such as TLRs (Toll-like receptors) ably
recognize the microbes at cell surfaces, whereas PRRs such as
nucleotide oligomerization domain (NOD) like receptors that are
localized in the cytosol can sense and recognize the intracellular
pathogens [10]. A recent genome wide study in Chinese leprosy
patients has provided vital insights on the role of NOD2
(rs9302752A/G), LRRK2 (rs1873613A/G) and RIPK2
(rs40457A/G and rs42490G/A) variants in regulating the
leprosy infection [7]. In addition, the expression of these genes
has been shown to up regulate in leprosy in comparison to
normal tissues [11]. The Nucleotide-binding oligomerization
domain 2 (NOD2) located on the long arm of chromosome 16
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e73103
(16q21) is an intracellular microbial sensor for muramyl
dipeptide, a component of bacterial peptidoglycan [12].
Dysregulation in NOD2 signalling is associated with pathogenesis
of many inflammatory disorders [13] and is also associated with
triggering of IL-32 dependent dendritic cell programming in
leprosy [14]. The cytosolic pattern recognition receptor NOD1
and NOD2 also activates the RIPK2 gene [15]. The gene
encoding receptor- interacting serine-threonine kinase 2 (RIPK2)
located on the long arm of chromosome 8 (8q21) is essential for
signaling through the Toll-like receptors [15,16]. In addition,
the RIPK2 interaction with NOD2 enhances NF-kB activity
making it an important player in cellular immune response [17].
The Leucine-rich repeat serine/threonine-protein kinase 2
(LRRK2) variants located on the long arm of chromosome 12
(12q12) are well documented as a common cause for parkinson
disease [18]. Also LRRK2 gene variants were also documented
for their role in inflammatory diseases [19] and to microbial
infections [20,21]. During onset of early leprosy infection, M.
leprae antigens are presented to CD4+T cells, which activate the
Th1 responses resulting in interferon gamma production leading
to macrophages maturation and subsequent killing. NOD2 and
RIPK2 regulate the interferon- gamma production [7].
Initiation of NOD2 signalling is mediated by RIPK2 by an
ubiqutination process and involvement of TAK1 and nuclear
factor-kB essential modulator to the NOD2-RIPK2 complex leads
to the movement of NF-kB to the nucleus and subsequent
activation of NF-kB target genes [22]. NOD2-mediated signaling
pathway plays an essential role in the immunological control of
intracellular bacteria. We investigated the possible association of
gene variants NOD2 (rs9302752A/G), LRRK2 (rs1873613A/G)
and RIPK2 (rs40457A/G and rs42490G/A) that are vital for
NOD2 signalling and subsequent activation of the NF-kB complex
in a cohort of clinically classified leprosy patients.
Materials and Methods
Ethical Statement
Informed written consent was received from all leprosy patients.
The study was approved by the research advisory committee and
institutional ethical committee of LEPRA- Blue peter public health
research centre, Hyderabad, India. Informed written consent was
also obtained from all the normal individuals and the institutional
ethical committee of CCMB has approved this study.
Sampling
All the leprosy patients studied (n= 211) were outpatients and
were recruited at the LEPRA- Blue Peter Public Health and
Research Centre (BPHRC) in Hyderabad, India [23]. Patients
were clinically evaluated and graded by the physicians either as a
paucibacillary (PB, n = 74) or multibacillary (MB, n= 137) group,
based on WHO standards [24]. Based on the number of lesions
and presence of acid-fast bacilli (AFB) in skin slit smears taken
from at least five different places of the body (both earlobes, both
halves of the forehead, at least one from one of the lesions) leprosy
patients were classified. More than five lesions as well as presence
of acid fast bacilli in any of the smears precludes a multibacillary
diagnosis, while a number of less than five lesions and, more
importantly, a lack of acid fast bacilli in any of the smears is
considered as the paucibacillary presentation. In addition to the
patients, blood samples from individual controls (n = 230) were
collected from adult males and females (18–35 years) form the
same ethnicity.
Genotyping
DNA was isolated from blood utilizing the DNeasy Blood and
Tissue kit (Qiagen, Germany) following the protocol of the
manufacturer. The primer sequences utilized for genotyping with
primer specific annealing temperatures is summarized in Table 1.
In brief: PCR was carried out in a 20 ml reaction volume with 5 ng
of genomic DNA, 16 PCR buffer (20 mM Tris-HCl pH 8.4,
50 mM KCl, 1.5 mM of MgCl2; Qiagen), 0.125 mM of dNTPs,
0.5 mM of each primer and 1 U Taq DNA polymerase (Qiagen,
Hilden, Germany) on a PTC-200 Thermal cycler (MJ Research,
USA). Thermal cycling parameters for amplification were: initial
denaturation at 94uC for 5 min, followed by 35 cycles of
respectively 15 sec at 94uC for denaturation, 60 sec at primer
specific annealing temperature, and 60 sec at 72uC extension. This
was followed by a final extension of 10 min at 72uC. PCR
products were cleaned up using Exo-SAP-IT (USB, Affymetrix,
USA) and 1 ml of the purified product were directly used as
templates for sequencing, using the BigDye terminator v. 2.0 cycle
sequencing kit (Applied Biosystems, USA) on an ABI 3130 XL and
ABI 37306L DNA sequencer, according to the manufacturer’s
instructions. Polymorphisms were identified by assembling the
sequences with respective reference sequences obtained from
SNPper database (http://snpper.chip.org) using Codon code
Aligner 4.0 software (http://www.codoncode.com/) and were
reconfirmed visually from their respective electropherograms.
Statistical Analysis
Data was analyzed using STATA and the level of significance
was set to a p-value of ,0.05. The distribution of genotypes
between control and leprosy patients, as well as between controls
and clinically classified patients were analyzed by two tailed fisher
exact tests. Genotype or haplotype frequencies were analyzed by
simple gene counting and expectation-maximum (EM) algorithm
and the significance of deviations from Hardy-Weinberg equilib-
rium was tested using the random-permutation procedure as
implemented in the Arlequin v. 3.5.1.2 software. (http://lgb.unige.
ch/arlequin). The comparison of Linkage disequilibrium (LD) for
RIPK2 variants for each patient group as well as for controls were
computed using the Haploview v4.2 software that utilizes a default
algorithm and this algorithm ignores markers with minor allele
frequencies (MAF) ,0.05.
Results
The observed distribution of genotypes and alleles in both
clinically classified patients and controls were summarized in
Table 2. The observed genotype and allele frequencies of all
studied SNPs in clinically classified patient groups and controls
were in Hardy-Weinberg equilibrium (P.0.05) except for the
NOD2 SNP rs9302752 (P,0.05). Therefore the NOD2 SNP
rs9302752 was excluded for further association analysis.
In LRRK2 gene locus, we observed that the minor allele LRRK2
rs1873613A and homozygous genotype rs1873613AA were more
frequent in leprosy patients than in controls conferring an
increased risk of leprosy (OR=1.7, 95% CI= 1.25–2.2,
P= 0.0003 and OR=2.04, 95% CI= 1.2–3.6, P = 0.007, respec-
tively). Whereas major allele LRRK2 rs1873613G and homozygous
genotype rs1873613GG were observed less frequently in patients
compared to controls conferring a decreased risk of leprosy
(OR=0.61, 95% CI=0.45–0.8, P= 0.0003 and OR=0.56, 95%
CI= 0.37–0.83, P= 0.0028, respectively). When clinically classi-
fied paucibacillary (PB) patients were compared to controls, a
similar trend was observed with a stronger significance (for the
minor allele rs1873613A: OR=2.77, 95% CI= 1.9–4.1,
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P,0.0001; for the homozygous genotype rs1873613AA: OR=4.1,
95% CI=2.1–7.9, P =P,0.0001). These results may confer that
the LRRK2 rs1873613A/G contributed to the progression of
paucibacillary leprosy. However, there was no significant differ-
ence of allele and genotype frequencies in comparison to
multibacillary (MB) patients with controls (Table 2). In addition,
we did not observe any significant difference of heterozygous
genotype frequency in all comparisons.
Two loci of RIPK2 gene (rs40457A/G and rs42490G/A) were
investigated in this study. However, no significant difference of
allele and genotype frequency of neither SNP rs40457A/G or
rs42490G/A was observed in all the comparisons. In leprosy
patients, both the studied RIPK2 variants were observed to be in
high LD [Leprosy patients (D9=0.64, LOD=12.72, r2=0.2), MB
patients (D’ = 0.53, LOD=5.84, r2=0.56), PB patients (D9=0.84,
LOD=7.58, r2=0.34)], whereas in controls it was observed in a
low degree of linkage disequilibrium (D9=0.38, LOD=3.2,
r2=0.06)]. We reconstructed haplotype based on these two
studied RIPK2 SNPs (rs40457A/G and rs42490G/A). Four
haplotypes and their frequencies were observed including AG,
AA, GA and GG. The RIPK2 haplotype GA was observed more
frequently in leprosy patients compared to controls inferring an
increased risk of leprosy (OR=1.46, 95% CI= 1.02–2.1,
P = 0.036), whereas RIPK2 haplotype AA was observed less
frequently in leprosy patients compared to controls inferring a
protection against leprosy (OR=0.69, 95% CI= 0.49–0.97,
P = 0.028). In addition, RIPK2 haplotype GA was observed more
frequently in paucibacillary (PB) patients in comparison to controls
inferring an increased risk of leprosy (OR=1.8, 95% CI= 1.1–2.8,
P = 0.018). Furthermore, there was no significant difference of
RIPK2 haplotype frequencies in comparison between multi-
bacillary (MB) patients with controls (Table3).
Discussion
All the four studied innate immune gene variants were
hypothesized to play a significant role in controlling the
interferon-gamma production and considered as vital modulators
for NF-kB [7]. We investigated the role of gene variants in NOD2
(rs9302752A/G), LRRK2 (rs1873613A/G) and RIPK2 (rs40457A/
G and rs42490G/A) based on a recently published genome-wide
association study (GWAS) that utilized Han Chinese population
[7]. Although the studied sample size was lower, the frequencies of
all four studied variants were in accordance with Han Chinese
population and also in a Gujarati Indian population as reported in
HapMap database. The minor allele of NOD2 rs9302752A/G
variant was observed at a similar frequency (0.28) in the studied
Indian population to reported frequencies in Han Chinese
population (0.22). However, the NOD2 rs9302752A/G variant
was not in Hardy-Weinberg equilibrium in Indian clinically
classified leprosy patients and marginally significant in control
group. The major allele of LRRK2 rs1873613A/G variant was also
observed at a similar frequency (0.68) compared to reported
frequencies in Gujarati Indians in Houston, Texas (GIH) (0.61) as
reported in the NCBI Hapmap database. The minor allele of
studied RIPK2 variant rs40457A/G was observed at a similar
frequency (0.21) when compared to reported frequencies in Han
Chinese (0.25) and in Gujarati Indians in Houston, Texas (GIH)
(0.30), whereas the minor allele of RIPK2 rs42490A/G was
observed at a similar frequency (0.41) when compared to reported
frequencies in Han Chinese (0.45) and in Gujarati Indians in
Houston, Texas (GIH) (0.40).
NOD2 is an intracellular microbial sensor of the innate immune
system that can act as a potent activator and regulator of
inflammation in mycobacterial infections [10,25]. Mutations in the
gene encoding NOD2 in humans have been associated with
Crohn’s disease (CD) [26], Blau syndrome (BS) [27], and early
onset sarcoidosis (EOS) [28]. In addition, the studied NOD2
variant (rs9302752A/G) was associated with susceptibility to
tuberculosis and leprosy in Chinese and Vietnamese population
[7,29,30]. NOD2 signaling pathways are activated by a CARD
effector domain that causes inflammation by the activation of NF-
kB and MAP kinase pathways [10]. Studies have documented the
fact that stimulation of NOD proteins are associated with
enhanced pro inflammatory cytokine production to M. leprae
infections [31] and this is well achieved by the recognition of
conserved microbial domains by PRRs. Therefore, any alteration
in the gene function of PRR domain may possibly reflect towards
leprosy susceptibility. Also it was shown that phenotypes of mouse
deficient with NOD2 and RIPK2 revealed a failure to produce
inflammatory cytokines to initiate Th1 responses [32]. In contrast
to Han Chinese population [7] we observed that NOD2
rs9302752A/G variant was not in Hardy-Weinberg equilibrium
in studied Indian population, therefore the contribution of this
variant to leprosy susceptibility remains unclear. The possibilities
for the studied NOD2 variant not in HWE can be due to the fact
that Indian populations have been following strict endogamy
marriage practices for last tens of thousands years, hence every
population acquired unique set of genetic variations. In this study,
the leprosy patients represent different ethnic groups from south
India and the number from each group is very less. Nevertheless in
this study, we always employed ethnically matched control
individuals from the same population to avoid the role of
Table 1. Investigated SNP variants in leprosy patients and controls.
SNP ID Locus Gene SNP Primer Pairs (59–39) Tm [6C]
rs9302752 16q21 NOD2 A/G F: GCCTTTGTTTTCGCAGTTCCTTCAG 55
R: CCTCGGTGACCACTTCTCTGCATTC
rs1873613 12q21 LRRK2 A/G F: CACCCAAGACACACAAGGAAAAAGCATATA 55
R: GCCTTCTTACGTTTTACCTCCCCCTCTT
rs40457 8q21 RIPK2 A/G F: GATTTTCCCCCAGAAGAAGG 50
R: GCAGGAAAATGAATCCATGA
rs42490 8q21 RIPK2 G/A F: ACCCACTTCCTCCCTACCACAATCTG 55
R: GCGGAATAGCTGGATCTCTCACACA
doi:10.1371/journal.pone.0073103.t001
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Table 2. Distribution of investigated NOD2, RIPK2, and LRRK2 variants in clinically classified leprosy patients and controls.
Loci
Patients
n =211(%)
MB (LL+LB)
n =137(%)
LL
n=62 (%)
LB
n=75 (%)
PB (BT+TT)
n=74 (%)
BT
n=70 (%)
TT
n=4 (%)
Controls
n =230 (%) Patients vs. Controls MB vs. Controls PB vs. Controls
OR (95% CI) P value OR (95% CI) P value OR (95%C I) P value
NOD2_rs9302752
AA 120(56.9) 84 (61.3) 52(83.9) 32 (42.7) 36 (48.6) 34 (48.6) 2 (50) 114(49.6) NA NA NA
AG 58 (27.5) 32 (23.4) 9 (14.5) 23 (30.7) 26 (35.1) 25 (35.7) 1 (25) 104(45.2) NA NA NA
GG 33 (15.6) 21 (15.3) 1 (1.6) 20 (26.6) 12 (16.2) 11 (15.7) 1 (25) 12 (5.2) NA NA NA
A 298(70.6) 200(73) 113 (91) 87 (58) 98 (66.2) 93 (66.4) 5 (62.5) 332(72.2)
G 124(29.4) 74 (27) 11 (9) 63 (42) 50 (33.8) 47 (35.6) 3 (37.5) 128(27.8) NA NA NA
LRRK2_rs1873613
GG 73 (34.6) 56 (40.9) 27(43.6) 29 (38.7) 17 (23) 16 (22.8) 1 (25) 112(48.7) 0.56 (0.37–0.83) 0.0028 NS 0.31 (0.16–0.6) 0.0001
AG 93 (44.1) 62 (45.2) 25(40.3) 37 (49.3) 31 (41.9) 30 (42.9) 1 (25) 91 (39.6) NS NS NS
AA 45 (21.3) 19 (13.9) 10(16.1) 9 (12) 26 (35.1) 24 (34.3) 2 (50) 27 (11.7) 2.04 (1.2–3.6) 0.007 NS 4.1 (2.1–7.9) 0.000014
G 239(56.6) 174 (63.5) 79(63.7) 95 (63.3) 65 (43.9) 62 (44.3) 3 (37.5) 315(68.5) 0.61 (0.45–0.8) 0.0003 NS 0.36 (0.240.54) 0.00000017
A 183(43.4) 100 (36.5) 45(36.3) 55 (36.7) 83 (56.1) 78 (55.7) 5 (62.5) 145(31.5) 1.7 (1.25–2.2) 0.0003 NS 2.77 (1.9–4.1) 0.00000017
RIPK2_rs40457
AA 117(54.5) 77 (56.2) 32(51.6) 45 (60) 40 (54) 37 (52.9) 3 (75) 144(62.6) NS NS NS
AG 79 (37.4) 50 (36.5) 25(40.3) 25 (33.3) 29 (39.2) 28 (40) 1 (25) 74 (32.2) NS NS NS
GG 15 (7.1) 10 (7.3) 5 (8.1) 5 (6.7) 5 (6.8) 5 (7.1) 0 12 (5.2) NS NS NS
A 313(74.2) 204 (74.5) 89(71.8) 115(76.7) 109 (73.6) 102(72.9) 7 (87.5) 362(78.7)
G 109(23.8) 70 (25.5) 35(28.2) 35 (23.3) 39 (26.4) 38 (27.1) 1 (12.5) 98 (21.3) NS NS NS
RIPK2_rs42490
GG 82 (38.9) 55 (40.1) 23(37.1) 32 (42.7) 27 (36.5) 26 (37.1) 1 (25) 85 (37) NS NS NS
GA 90 (42.7) 59 (43.1) 23(37.1) 36 (48) 31 (41.9) 28 (40) 3 (75) 104(45.2) NS NS NS
AA 39 (18.4) 23 (16.8) 16(25.8) 7 (9.3) 16 (21.6) 16 (22.9) 0 41 (17.8) NS NS NS
G 254(60.2) 169 (61.7) 69(55.6) 100(66.7) 85 (49.2) 80 (57.1) 5 (62.5) 274(59.6)
A 168(39.8) 105 (38.3) 55(44.4) 50 (33.3) 63 (50.8) 60 (42.9) 3 (37.5) 186(40.4) NS NS NS
doi:10.1371/journal.pone.0073103.t002
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population stratification in allelic difference between cases and
controls.
For the investigated LRRK2 rs1873613A/G variant the
contribution was observed of this particular variant in the studied
Indian population. The minor allele A and homozygous genotype
AA contributed towards an increased risk of leprosy whereas the
major allele G and homozygous genotype GG predisposed as
protective factors for leprosy. Our results also showed that LRRK2
rs1873613A/G variant significantly contributed to the develop-
ment of paucibacillary leprosy but not multibacillary leprosy.
Earlier studies have demonstrated that a trend towards an
association between the variant and susceptibility to leprosy [7].
The association study of LRRK2 rs1873613A/G variant with
leprosy was also conducted in a Vietnamese population, however
the association was not statistically significant [30]. LRRK2 is
associated with various diseases, including Parkinson’s disease,
cancer, and leprosy [33] and also known to be associated with
susceptibility to the chronic autoimmune Crohn’s disease, which is
an inflammatory disorder [34]. Higher expression of LRRK2 is
observed in macrophages and monocytes revealing its significance
in the innate immune system [35] and in leprosy per se. Most of
the replication studies do not document similar effects of a
particular gene variant contribution when investigated in different
ethnicities [36–38]. In the reported GWAS study from Han
Chinese population, the LRRK2 rs1873613A allele was observed as
a major allele whereas the rs1873613G variant is a minor allele and
confers decreased risk towards leprosy in Chinese patients. [7].
Additionally similar allele frequencies were reported in the
Vietnamese population [30]. However in the studied Indian
population, the LRRK2 rs1873613G allele was observed as a major
allele whereas the rs1873613A variant increased the risk towards
leprosy in the investigated Indian cohort. There seems a switch of
allele frequencies between populations and the clinical significance
of the studied variant likely depends on the context of the studied
ethnicities. Additionally India is inhabited by the very first out-of-
Africa modern human about 65,000 years ago. Since then they
remain unmixed, therefore the genome of Indian populations are
unique and the allele frequency differ significantly when compare
to the rest of the world [39]. LRRK2 gene has been shown to play
an important role in different diseases including Parkinson,
Crohn’s and inflammatory diseases [18,19,21,33]. Interestingly,
LRRK2 has been also demonstrated to be an IFN-gamma target
gene, involve in different immune response signaling such as NF-
kB pathways, and contribute to the antibacterial activity of the
macrophages, in which LRRK2 plays a role in the killing of
intracellular bacteria such as S. typhimurium [20]. In addition, the
expression of LRRK2 gene was significantly higher in leprosy
compared to normal tissues [11]. This suggested that LRRK2
might contribute crucially to the immune response against
intracellular bacteria M. leprae.
The RIPK2 rs40457A/G and rs42490G/A variants did not
confer any significance results at allele and genotype levels. A
larger sample size will be required in order to detect any
significance for the both studied RIPK2 variant at allele level.
We observed the reconstructed haplotypes AA and GA based on
two variants rs40457A/G and rs42490G/A to be significantly
associated with leprosy susceptibility. In addition, the haplotype
GA also conferred to an increased risk of paucibacillary leprosy
development. Recently, a replicate study conducted in a
Vietnamese population showed that the variant RIPK2
rs42490G/A was significantly associated with leprosy whereas
the significance was not revealed for the variant RIPK2 rs40457A/
G [30].Studies have established the fact that RIPK2 interaction
with NOD2 enhances NF-kB activity making it an important
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player in cellular immune response [17]. A recent study has also
documented on the interaction between the NOD2 and RIPK2 loci
(NOD2-RIPK2 complex) in activating the NF-kB pathway as a
part of the host defence response to leprosy infection [40].
Therefore, our results indicate that a possible shared mechanisms
as a basis for the development of these two clinical forms of the
disease as hypothesized earlier [7].
In conclusion, our study validated the association of gene
variants involved in intracellular sensing that are believed to play a
role in immunologic control of intracellular bacteria M. leprae in
Indian leprosy patients. Overall the study increases our under-
standing on complex molecular and cellular mechanisms that are
regulated by the intracellular pathogen M. leprae during its clinical
course.
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a b s t r a c t
The heterodimeric transporter associated with antigen processing (TAP) gene loci is known to play a vital
role in immune surveillance. We investigated a possible association of gene polymorphisms both in TAP1
and TAP2 in a cohort of clinically classified leprosy patients (n = 222) and in ethnically matched controls
(n = 223). The TAP1 and TAP2 genes were genotyped for four single nucleotide polymorphisms TAP1
(rs1057141 Iso333Val and rs1135216 Asp637Gly) and TAP2 (rs2228396 Ala565Thr and rs241447
Ala665Thr) by direct sequencing and ARMS-PCR. The minor allele of TAP1 637G contributes to an
increased risk to leprosy compared to controls (OR: 1.68, 95% CI 1.2–2.36, P = 0.0057). An increased risk
for the variant minor allele of the TAP1 637G to multibacillary (BL + LL) or paucibacillary (BT + TT) infec-
tions was also observed [multibacillary vs. controls (OR: 1.56, 95% CI 1.07–2.28, P = 0.054); paucibacillary
vs. controls (OR: 1.92, 95% CI 1.21–3.01, P = 0.013)]. In the dominant model, the genotypes of the TAP1
rs1135216AG + GG additionally contributed to an increased risk. Overall our findings demonstrate that
the TAP1 gene variant (rs1135216 Asp637Gly) influences the susceptibility to clinically classified leprosy
patients in Indian population.
 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights
reserved.
1. Introduction
Leprosy is caused by an obligate intracellular pathogen Myco-
bacterium leprae. The clinical presentation is governed by various
host attributes, which presents leprosy over a five point Ridley–Jo-
pling spectrum with stable lepromatous (LL) and tuberculoid (TT)
at the polar ends and unstable Borderline tuberculoid (BT), Border-
line (BB) and Borderline lepromatous (BL) between the polar ends.
By standards of WHO classification, all BL and LL individuals repre-
sented as multibacillary (MB) patients, whereas the BT and TT indi-
viduals represented the paucibacillary (PB) patients. Susceptibility
to leprosy upon exposure to the pathogen is far limited to 1% [1]
and host genetic factors had been shown to influence the infection
of M. leprae and its clinical outcome [2,3].
The pathogen driven selection on immune genes can potentially
alter the primed sequence in the promoter regions and can direct
to substantial changes in gene expression [4]. Family studies, seg-
regation analyses, and twin studies have provided evidence that,
host genetic factors influence the susceptibility to leprosy [5–7].
Recent studies have demonstrated that gene variants in the chro-
mosome 6 and 10 are linked to susceptibility to leprosy [8–10,1].
In addition, candidate gene analysis and genome wide studies have
implicated various variants in the HLA locus and SNPs (single
nucleotide polymorphisms) in genes regulating the cytokines
influence susceptibility or resistance towards the infection
[8,11,12]. In particular, a variant in the promoter region of the
TNF-a gene has revealed contradictory results within populations
[6,13–16]. A recent study from India reported a strong association
of SNP variants located in BAT1, LTA, TNF genes and BTNL2-DRA
interval within HLA (6p21.3) with leprosy susceptibility in two
independent sets of North Indian population which was replicated
in a geographically distinct East Indian population [17]. The first
genome wide linkage scan from India mapped leprosy susceptibil-
ity to chromosome 10p13 followed by further studies indicating
the association of this locus with tuberculoid leprosy [9,10,1].
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The MRC1 gene encoding the human mannose receptor (MR) is lo-
cated in the 10p13 region and non-synonymous SNP in exon 7 of
the MRC1 have been suggested as leprosy a susceptibility factor
[18]. The SNPs in the immunomodulatory gene Interleukin-10
(IL10-819C/T) promoter has been suggested to be associated with
leprosy susceptibility in Brazil and India [15,19,20]. In addition,
chromosome 20p12, 6q25 have been reported to be associated
with susceptibility to leprosy [20,21]. Investigation of such SNPs
in the immune genes will possibly reflect the level of susceptibility
to any infectious disease. One such gene of interest is Transporter
associated with antigen presentation (TAP) gene locus that map to
the long arm of chromosome 6 (6p21.3).
The delivery of major histocompatibility complex (MHC) class I
molecules from cytosol to the endoplasmic reticulum is facilitated
by transporter associated with antigen processing (TAP), a hetero-
dimer composed of two subunits TAP1 and TAP2. Earlier studies
suggested that polymorphisms in the immune genes such as hu-
man leukocyte antigen (HLA), mannose binding lectin (MBL2), lym-
photoxin-a (LT-a), ficolin-2 (FCN2) and Interferon-gamma
receptor-1 (IFNcR1) are significantly associated to leprosy outcome
[2,22–25]. In addition, polymorphisms in the TAP genes are known
to be associated with other diseases including autoimmune dis-
eases such as ankylosying spondilytis, rheumatoid arthritis and
in tuberculosis [26–29]. Earlier studies on TAP gene polymor-
phisms have been associated to tuberculosis [29,30,27]. Since the
causative organism of both leprosy and tuberculosis represent
the same genus Mycobacterium, we aim to investigate the associa-
tion of TAP1 (rs1057141 Iso333Val and rs1135216 Asp637Gly) and
TAP2 (rs2228396 Ala565Thr and rs241447 Ala665Thr) gene poly-
morphisms to the infection outcome in Indian leprosy cohort with
clinically classified patient groups.
2. Materials and methods
2.1. Study subjects
Leprosy patients (n = 222) reporting to LEPRA projects, BPHRC-
Blue Peter Public Health Research Centre were enrolled for the
study. Individuals were characterized either as Borderline (BL)
[n = 80, Male/Female ratio = 61/19, Mean age = 36.9 ± 14.1], Lepro-
matous (LL) [n = 66, Male/Female ratio = 51/15, Mean
age = 58.1 ± 14.5], Borderline Tuberculoid (BT) [n = 73, Male/Fe-
male ratio = 32/41, Mean age = 33.3 ± 12], and Tuberuculoid (TT)
[n = 3, Male/Female ratio = 1/2, Mean age = 44 ± 6.5], based on their
clinical manifestations as graded by the physicians by slit skin
smear examination, histopathology and routine diagnostic proce-
dures. All recruited individuals are further grouped on WHO clas-
sification either as paucibacillary or multibacillary patients. All
BL and LL individuals represented the mutibacillary group
[n = 146, Male/Female ratio = 112/34, Mean age = 40.4 ± 16.1],
whereas BT and TT individuals represented the paucibacillary
group [n = 76, Male/Female ratio = 33/43, Mean age = 45 ± 18.8].
A total of 223 ethnically matched control individuals from the
same socio-ethnic and geographical region have been utilized from
DNA data bank of the Centre for Cellular and Molecular Biology
[Male/Female ratio = 148/75, age: 30–55]. None of them had family
history of leprosy or tuberculosis or other related disorders. In-
formed written consent was obtained from all study subjects.
The study was approved by the Institutional Ethical Committee
(IEC) of LEPRA-BPHRC.
2.2. Genotyping
2.2.1. Direct sequencing
DNA was extracted using Qiagen DNeasy kit (Qiagen, Hilden,
Germany) following manufacturer’s instructions. For the TAP1
gene locus, the SNP #rs1057141 (A/G) in exon 4 and #rs1135216
(A/G) in exon 10; whereas for TAP2 gene locus the SNP
#rs2228396 (G/A) and the SNP #rs241447 in exon 10 and were
genotyped by direct sequencing. The primer pairs utilized for
TAP1_rs1057141 was 333F: 50-CCCTGGCATCCTGGCTCATTGTTAG-
3’ and 333R: 5’-AGCGGGCCAACTCCATGAACATAC-3’ whereas for
TAP1_rs1135216 was 637F: 50-CCCCTATCCAGCTACAACCGTCAGA-
30 and 637R: 50-GAAGCAAGATTGGGTGGGATATAGC-30. For the
TAP2 loci, the primer pairs utilized were TAP2_rs2228396 was
565F: 5’- GCCCCTGTCCCTGCTGCAC-3’ and 565R: 5’-GGGCAGAG-
GAACAGCAAACATCAAG-3’ whereas for TAP2_rs241447 was 665F:
50-GCCTTTATCTACTGCCCTTTCCTACCT-30 and 665R: 50-GGCCGCA-
CAGCTCTAGGGAAACTCA-30. In brief: 10 ng of genomic DNA was
amplified in a 20 ll volume of reaction mixture containing 1
PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM of MgCl2),
0.125 mM of dNTPs, 0.25 mM of each primer and 1 U Taq DNA
polymerase (Qiagen, Hilden, Germany) on a PTC-200 Thermal cy-
cler (MJ Research, USA). Thermal cycling parameters for amplifica-
tion of both TAP1 and TAP2 loci were: initial denaturation at 94 C
for 5 min, followed by 35 cycles of 30 s at 94 C denaturation, 45 s
at loci specific annealing temperature (60 C for TAP1_rs1057141,
TAP1_rs1135216, TAP2_rs2228396 and 65 C for TAP2_rs241447),
1 min 30 s at 72 C extension, followed by a final extension of
2 min at 72 C. PCR products were cleaned up using Exo-SAP-IT
(USB, Affymetrix, USA) and 1 ll of the purified products were se-
quenced using the BigDye terminator v. 1.1 cycle sequencing kit
(Applied Biosystems, USA) and ABI 3130XL and ABI3730 DNA se-
quencer, according to the manufacturer’s instructions. Polymor-
phisms were identified by assembling the sequences with
respective reference sequences (for TAP1: NM_000593 and for
TAP2: NM_018833) using Codon code Aligner 4.0 software
(http://www.codoncode.com/) or AutoAssembler (Applied Biosys-
tems, USA) and were reconfirmed visually from their respective
electropherograms.
2.3. ARMS PCR (Amplification refractory mutation system)
Initially we employed a tetra primer amplification refractory
mutation system – PCR (ARMS-PCR) using previously published pri-
mer pairs were performed to genotype four SNP variants in the TAP1
and TAP2 gene loci [31] in one hundred controls and one hundred
patients. For the TAP1 gene locus, the SNP #rs1057141 (A/G) in exon
4 and #rs1135216 (A/G) in exon 10; whereas for TAP2 gene locus
the SNP #rs2228396 (G/A) and the SNP #rs241447 in exon 10 were
genotyped by ARMS-PCR. Thermal cycling parameters and pro-
gramming conditions were 95 C for 1 min followed by 30 cycles
of 95 C for 90 s, appropriate annealing for 90 s (68 C for TAP1
and 60 C for TAP2) and 72 C for 60 s and a final extension at
72 C for 10 min: Amplicons were separated on a 2% agarose gel
by applying a constant voltage of 90 V. To reconfirm for their repro-
ducibility for SNPs, fifty individual samples each from control and
patient group were sequenced using the BigDye terminator v. 2.0
cycle sequencing kit (Applied Biosystems, USA) on an ABI 3130
DNA sequencer, according to the manufacturer’s instructions.
2.4. Statistical analysis
The sample size was calculated using with OpenEpi program
(http://www.openepi.com) with 80% power and 95% confidence
interval. Statistical analysis was performed using Intercooled Stata
v. 9.1 (STATA Corporation, Texas, USA) to determine the differences
in allele frequencies and genotype distributions. The level of signif-
icance was set at P < 0.05. In addition, different genetic models
including dominant (major genotype vs. heterozygous + homozy-
gous minor genotype), recessive (major genotype + heterozygous
vs. homozygous minor genotype) and allelic model were
804 V. Shinde et al. / Human Immunology 74 (2013) 803–807
investigated to detect any possible associations of then studied
variants between clinically classified patients compared to con-
trols. P-values were corrected for multiple comparisons using Bon-
ferroni procedure. Genotype frequencies were determined by
simple gene counting and by using the expectation-maximum
(EM) algorithm. The significance of deviation from Hardy–Wein-
berg equilibrium was tested using the random-permutation proce-
dure as implemented in the Arlequin v. 3.5.1.2 software [32].
3. Results
Two of the observed locus (one in TAP1 rs1057141 and one in
TAP2 rs241447 Ala665Thr) was not in Hardy–Weinberg equilib-
rium. Hence these two loci (TAP1 rs1057141 and TAP2 rs241447
Ala665Thr) were not considered for further analysis. The distribu-
tion of TAP1 genotypes and allele frequencies in clinically classified
patients and in matched controls based on different genetic models
is summarized in Table 1. The TAP1 rs1135216 (Asp637Gly) in exon
10 was observed to be a susceptibility factor. The variant minor al-
lele of the TAP1 rs1135216G locus was observed to be higher in pa-
tients than in control individuals (OR: 1.68, 95% CI 1.2–2.36,
P = 0.0057) Table 1. When clinically classified paucibacillary
(BL + LL) or multibacillary (BT + TT) patients were compared to
controls, the variant minor allele of the TAP1 rs1135216G was also
observed to increase the risk of infection [MB vs. Controls (OR:
1.56, 95% CI 1.07–2.28, P = 0.054); PB vs. Controls (OR: 1.92, 95%
CI 1.21–3.01, P = 0.013)] Table 1. Similar observations were in-
ferred in dominant genetic model for this variant TAP1
rs1135216 when compared between patients and controls or be-
tween clinically classified patient groups and controls [Patients
vs. Controls (OR: 2.01, 95% CI 1.34–3.03, P = 0.0012); MB vs. Con-
trols (OR: 1.92, 95% CI 1.21–3.03, P = 0.011); PB vs. Controls (OR:
2.20, 95% CI 1.25–3.90, P = 0.015)] Table 1. No significant contribu-
tions were observed when compared between any of the clinically
classified patient groups. For the TAP2 rs2228396 (Asp637Gly) in
exon 10, we did not observe any significant contributions (after p
value corrections) either between patients and controls or between
clinically classified patient groups compared to controls. Since each
locus in TAP1 (rs1057141) and TAP2 (rs241447) were not in Hardy–
Weinberg, hence reconstruction of haplotypes was not executed.
4. Discussion
Our aim of the study was to investigate the association of TAP
gene polymorphisms with susceptibility to leprosy. The TAP gene
encoding the TAP protein lies between HLA-DP and HLA-DQ of
chromosome 6 which has been implicated as a leprosy susceptibil-
ity locus in genome wide scan studies [8]. The HLA class I haplotype
HLA-A⁄1102-B⁄4006-Cw⁄1502 is reported to be significantly associ-
ated with leprosy susceptibility in Indian population [11]. Among
the class II genes the HLA-DRB1 locus, more specifically DRB1⁄15
and DRB1⁄16, are associated with leprosy susceptibility in India
[33,34], Thailand [35] and Brazil [36,7] and HLA DRB⁄15 has been
reported to be associated with leprosy in Chinese population [8].
The HLA-DRB1⁄0405 has been reported to be associated with resis-
tance to multibacillary leprosy in Taiwanese population [37]. In
Indonesian population susceptibility to lepromatous leprosy has
been reported to be associated with HLA-DRB1⁄02, while resistance
to leprosy is associated with HLA-DRB1⁄12 [38].
The incompetence of the immune system to clear parasites de-
spite antigen recognition may be attributed to host genetic factors
[39]. One such factor can be polymorphisms in the immune recog-
nition domains. The HLA class I molecules play a crucial role in
adaptive immune system by presenting antigen peptides on the
cell surface. The active transportation of antigen peptides to the T
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endoplasmic reticulum is facilitated by transporters associated
with antigen presentation proteins. Hence the rationale is that
any polymorphism in this domain may influence the ability of anti-
gen recognition. A recent study reported that the heterozygous
genotype TAP1 637AG was observed to be a risk factor to tubercu-
losis in a Chinese population which is in accordance with our ob-
served results [29]. In a yet other study from our group in the
context of TAP polymorphisms and HIV positive individuals re-
vealed that genotypes GG (Val/Val) at position TAP1 333 and indi-
viduals with heterozygous genotypes GA (Gly/Asp) at TAP1 637
variants remain at higher risk of developing tuberculosis [27].
Our results indicate that the heterozygous genotype AG (TAP1
637) contributed towards increased susceptibility to leprosy in
clinically classified groups. The TAP1637 AG genotype has been re-
ported to be a risk factor in ankylosing spondilytis and cystic echi-
nococcosis [26,40] and the association of TAP1333 AA genotype
with protection in dengue hemorrhagic fever and dengue shock
syndrome [41]. However, another study revealed a significant in-
crease of homozygous AA genotype in TAP1333 and TAP1637 in Pol-
ish and UK patients affected with sarcoidosis and in Korean
patients with allergic rhinitis [42,43]. The clinical significance of
these alleles may likely vary depending on the disease context
and also on the allele distribution in world populations. The ob-
served allele frequencies for both TAP1 (#rs1057141 and
#rs1135216) and TAP2 gene (#rs2228396 and #rs241447) loci in
this study remained consistent with allele frequencies observed
in other world populations as inferred from the HapMap database.
The AG genotype indicating the presence of both isoleucine and va-
line at position 333 (codon) of TAP1 gene might affect peptide
transportation by down regulation of antigen presentation and
concerned immune responses, that may lead to a diffused immune
response against leprae antigen. In this context, the AG genotype at
TAP1 333 appears to be a risk factor for the disease and was sub-
stantiated by the fact that subjects with homozygous genotype
AA appear to be less susceptible. Our data revealed that for TAP1
637, Aspartic acid/Glycine heterozygote (AG genotype) remained
a risk factor for the leprosy. Inline with our results, other studies
on cystic echinococcosis, pneumonitis also reported AG (TAP1
637) genotype to be a risk factor [40,44].
Our results suggest that there is no significant contribution of
TAP2 variants to leprosy. Majority of the patient and control groups
expressed homozygous GG genotype coding for Alanine/Alanine at
position 565, which was in accordance with other studies on sar-
coidosis and ankylosing spondilytis [26,42,43]. Genotype AA cod-
ing for Threonine was not detected in either the patient or
control groups. These findings were well in accordance with a
study on ankylosing spondilytis where a very low frequency of
AA genotype was reported in the patient group [26]. The 665AA
genotype was observed less in both patients and controls. How-
ever, a positive association of 665AA genotype has been reported
in inflammatory rheumatoid arthritis in Finnish population [28].
Our results provide genetic evidence that polymorphism in the
TAP1 gene influences the susceptibility to leprosy in Indian popula-
tion. A plausible explanation on the effect of this variant may be
that the microbial peptides may not be recognized or ably bind
to MHC class I molecules thereby affecting the antigen transport
leading to a detrimental or minimal immune response.
To conclude, the TAP1 heterozygous genotype AG (#rs1135216
Asp637Gly) and the minor allele variant #rs1135216G contribute
towards an increased risk and infection levels. However, these
observations need to be confirmed and validated in larger popula-
tions. Further studies on functional characterization of SNPs at
transcriptional level may shed light on the association of these
polymorphisms. Overall, our study demonstrates a significant
association of TAP1 polymorphisms with leprosy outcome and
TAP1 may be a contributing factor in leprosy.
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Abstract 23 
Introduction: Leprosy, caused by Mycobacterium leprae, is a neglected tropical disease of the nerves 24 
and skin and is a major public health problem in tropical and sub-tropical countries. With the pathogen 25 
unable to grow in vitro and with a lack of a suitable animal model in vitro experiments provides a 26 
platform to understand the host-pathogen-interaction at the cellular level. 27 
Methods: Utilizing the peripheral blood mononuclear cells from individuals of different ethnic descent, 28 
we investigated the interactions of M. leprae antigen on monocytes and monocyte-derived 29 
macrophages by fluorescence-activated cell sorting. 30 
Results: M. leprae whole cell antigen up-regulated L-Selectin expression in monocytes by 20%. 31 
Additionally the CD163 expression is increased by 30% in macrophages. 32 
Discussion: Increased L-Selectin expression in activated monocytes indicates a higher mobility 33 
towards affected tissues, and up-regulation of CD163 provides a vital clue on the role of M2 34 
macrophages during the clinical progression. 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
44 
Introduction 45 
Leprosy is one of the neglected tropical diseases of the skin and the nerves and is caused by 46 
Mycobacteriumleprae. M.leprae depends highly on macrophages and Schwann cells as they are 47 
intracellular pathogens (1). Despite concerted efforts to eradicate the disease, leprosy in tropical and 48 
sub-tropical countries still remains amongst the most common causes for debilitating disabilities (2). 49 
But more than a health problem, leprosy is also a social stigma that decreases quality of life and 50 
indeed life expectancy of those affected (3). The disease exerts its influence predominantly in 51 
countries with a great disparity in access to medical services, namely Brazil, Indonesia, and India (2). 52 
It is also notable that in the aforementioned countries the new case detection rate has remained 53 
virtually stagnant since 2006, despite great efforts by World health organization’s “final push” program. 54 
Mycobacterium leprae survives in the human Schwann cells and macrophages by thoroughly 55 
changing their phenotype (4-6). This change in phenotype goes so far, that a recent discovery could 56 
prove that the bacteria are capable to change the phenotype of mouse Schwann cells back into a 57 
stem cell-like one (7). Those susceptible to the bacterium show no uniform reaction, making leprosy a 58 
disease with a spectrum of symptoms that is dependent on how a given immune system reacts to the 59 
threat (8). For a better understanding towards leprosy pathogenesis, investigation on the interaction of 60 
innate immune cells to M. leprae during the onset of infection at a cellular level is essential. 61 
Macrophages are important in this setting, as they are on the one side a main part of the cellular 62 
immunity, which is supposed to kill infected cells. On the other side they are one of the two main cell 63 
types in which Mycobacterium leprae can survive. Macrophages in leprosy are predominantly found in 64 
skin lesions. However, extraction of macrophages from the tissue biopsies remains complicated and 65 
cumbersome, a labor intensive exercise. Additionally, infected macrophages are scarce in patients 66 
with paucibacillary spectrum. Experimentation with Mycobacterium leprae is further aggravated by the 67 
small number of functioning animal models. The only two models known to enable a steady bacterial 68 
infection are the nine-banded armadillo (9) and the footpads of BALBc mice (10). 69 
Hence isolation of monocytes from PBMCs and further differentiation of monocytes to macrophages in 70 
vitro is a feasible method to investigate innate immune cell interactions with M.leprae. We therefore 71 
employed and standardized a novel approach to investigate the interactions of monocytes and 72 
macrophages with M. leprae by in vitro co-culture experiments utilizing M. leprae whole cell sonicate 73 
as antigen.  74 
L-Selectin, or CD62L, has been identified as an essential part of leukocyte migration, which includes 75 
the extravasation of monocytes into tissue in order to develop into macrophages at the site of infection 76 
or acute and chronic inflammation (11, 12). An extensive interplay between lack of L-Selectin and 77 
increase in inflammation causing cardiovascular disease has been proven, of which particularly 78 
arteriosclerosis is of interest in the context of M. leprae and M. tuberculosis infections, as in all three 79 
pathologies we find a thoroughly changed macrophage phenotype due to massive incorporation of 80 
low-density lipid droplets (13). The particular importance of L-Selectin in clearing inflammation has 81 
been underlined by the discovery that anti-CD62L antibodies efficiently inhibit the recruitment of 82 
monocytes and neutrophils to inflammatory sites (11). Observing the activity of L-Selectin in an 83 
inflammatory disease such as leprosy is therefore of great interest. 84 
Apart from fighting pathogens and threats by cancerous cells, macrophages also are responsible for 85 
cleaning up the sites of inflammation after an immunological intervention. Of particular importance to 86 
tissue repair is the M2 macrophage sub-population (14). It is, amongst other things, characterized by 87 
CD163, whose expression is characteristically up-regulated by the anti-inflammatory IL10, while the 88 
pro-inflammatory cytokines IFN-γ and TNF-α cause a decreased expression (15). It is therefore to be 89 
assumed that during the course of an active infection upon stimulation by a pathogen M2 macrophage 90 
activity, and thus CD163 expression, would decrease, and only increase after pathogenic threat had 91 
been repelled. We find strong evidence for this in other publications about the closely to M. leprae 92 
related M. tuberculosis: Matilla et al. proved that in tuberculous granulomas in macaques we find anti-93 
inflammatory macrophages expressing CD163 almost exclusively in the outer regions, adjacent to 94 
uninvolved tissue, and not in areas of high bacterial load (16). In vitro studies with an artificial infection 95 
of human monocytes by M. tuberculosis showed a moderate reduction of CD163 expression in 96 
monocytes derived from tuberculosis patients, and no significant change at all in monocytes derived 97 
from healthy controls (17). An increase in CD163 expression could not be observed in any case. 98 
These results were supported by a study from the university of Bern, in which immunohistochemical 99 
staining of patient samples derived from tuberculous granulomas revealed only a small number of 100 
CD163-positive samples (21%), as opposed to CD68 (90%) (18). Intriguingly, the picture almost 101 
reversed when compared to schistosomiasis-induced granulomas, where CD163 was expressed 102 
about twice as much as in tuberculosis-induced granulomas. 103 
We intended to find out whether the assumption that M2 macrophage activity, presented by CD163 104 
expression, is decreased during active bacterial threat would hold true in the case of a M. leprae 105 
infection. 106 
 107 
Methods 108 
Study population: We investigated monocytes and macrophages isolated from six healthy individuals 109 
who gave their signed written consent. They had no previous history of leprosy and none of them was 110 
on immune-suppressive medication during or four months prior to blood sampling. 111 
M. leprae antigen: The whole cell sonicate (WCS), (Cat#: NR-19329) of Mycobacterium leprae for our 112 
co-culture experiments was received with thanks from Biodefense and Emerging Infections Research 113 
Resources Repository (BEI). 114 
PBMC isolation: The peripheral blood was diluted 1:1 with RPMI 1640(PAA Laboratories GmbH, 115 
Cölbe, Germany). Using Ficoll PaqueTM Plus (GE Healthcare Europe, Frankfurt, Germany)cells were 116 
separated via density gradient centrifugation as described earlier (19). Subsequently, peripheral blood 117 
mononuclear cells (PBMCs) were isolated after centrifugation. 118 
Monocytes isolation: Monocytes were negatively isolated by utilizing the Dynabeads® UntouchedTM 119 
Human Monocytes Kit (Invitrogen, Karlsruhe, Germany). Purity of the isolated monocytes was 120 
checked by fluorescence activated cell sorting (FACS) via CD14-FITC- antibody (BD Biosciences, 121 
Heidelberg, Germany). The presence of CD62L and CD163 on the cell surface was also established 122 
via APC- and PE-labeled antibodies respectively (BD Biosciences, Heidelberg, Germany).The isolated 123 
monocytes were then incubated separately in a growth medium consisting of RPMI 1640 (PAA 124 
Laboratories GmbH, Cölbe, Germany) with 5% fetal bovine serum (PAA Laboratories GmbH, Cölbe, 125 
Germany), 1% L-glutamine (Invitrogen, Karlsruhe, Germany), and 1% Pen Strep (Invitrogen, 126 
Karlsruhe, Germany), in a cell culture plates at a concentration of 0.2 x106monocytes/mL. 127 
Monocytes harvest: Monocytes were harvested after three days of incubation by removing the 128 
supernatant and applying AccutaseTM(eBiosciences, Frankfurt, Germany) following manufacturer’s 129 
protocol. In brief: the supernatant was removed and the adherent cells were washed with phosphate-130 
buffered saline (PBS). Then Accutase was added at a volume of 10 ml per 75 cm2 surface area and 131 
the cells incubated at 37°C for 10 minutes for cells to detach. The detached cells were washed once 132 
with PBS. 133 
Activation of Monocytes: The harvested monocytes were incubated with 10µg/ml WCS overnight 134 
(approximately 18 hours), the other half was incubated without any activation and served as a baseline 135 
for comparisons. Incubation steps were performed with similar concentrations as done before with 136 
RPMI 1640 (PAA Laboratories GmbH, Cölbe, Germany) with 5% fetal bovine serum (PAA 137 
Laboratories GmbH, Cölbe, Germany), 1% L-glutamine (Invitrogen, Karlsruhe, Germany), and 1% Pen 138 
Strep (Invitrogen, Karlsruhe, Germany), in cell culture plates. After incubation, CD62L-expression on 139 
both activated and non-activated monocytes (identified through a CD14-FITC antibody) was measured 140 
by FACS (BD Biosciences, Heidelberg, Germany) and a CD62L-APC antibody (BD Biosciences, 141 
Heidelberg, Germany). 142 
Macrophages harvest and activation:  In parallel to monocytes isolation and harvest, monocytes were 143 
subsequently allowed to mature and differentiate to macrophages for six days. After incubation, the 144 
remaining incubated cells were harvested as above. After washing the cells, a portion of them was 145 
taken to check for maturation by FACS. Utilized markers were antibodies against CD14-FITC, CD62L-146 
APC, and CD163-APC (BD Biosciences, Heidelberg, Germany). Macrophages were harvested as 147 
described earlier for monocytes harvest procedure. The harvested macrophages were further 148 
incubated with 10µg/ml WCS for approximately 18 hours, the other half was incubated without any 149 
activation and served as a baseline for comparisons. Activation status after incubation was tested with 150 
the same antibodies as above (CD14-FITC, CD62L-APC, and CD163-APC). 151 
 152 
 153 
 154 
Results 155 
Monocytes maturation to Macrophages: 156 
After six days of incubation, CD14+cells showed an increase in internal complexity and size in FACS. 157 
Only approximately 4.5% of them were still CD62L+when compared to CD14+cells on day zero (Figure. 158 
1).When monocytes were only incubated for 3 days and then stimulated with WCS overnight, CD62L-159 
expression across individuals increased by 30% (Figure 2). 160 
Interaction of monocyte derived macrophages with M.leprae WCS: 161 
After incubation with WCS, the matured macrophages showed a significantly different phenotype when 162 
compared to non-activated macrophages (Table1). Both size and internal complexity, represented by 163 
the FSC and SSC values respectively, changed upon overnight stimulation with WCS (Figure 3).Upon 164 
activation with WCS, macrophages showed an up-regulation of CD163 that was more than 20% higher 165 
than that of non-stimulated controls (Table1, Figure 4). 166 
Discussion 167 
The nature of Mycobacterium leprae as a pathogen that cannot be grown in vitro and only to certain 168 
extents in vivo makes it essential to achieve an activation of cells of interest that is as close as 169 
possible to real pathogen-host interactions. We believe an activation via Mycobacterium leprae WCS 170 
achieves this. 171 
We utilized CD62L, or L-Selectin, as a marker of increased monocyte mobility and of maturation of 172 
monocytes into macrophages. L-Selectin is a cell adhesion molecule that plays an important role in the 173 
migration of leukocytes from the blood stream into tissues (12, 20, 21). Specifically, L-Selectin binds 174 
free-flowing monocytes to the endothelium and mediates extravasation into the tissue (22). Therefore 175 
a reduction in L-Selectin expression on the surface of the cell is an indicator of the change from a free-176 
flowing monocyte phenotype towards a tissue-bound macrophage phenotype. After three days of 177 
incubation, our cells showed a marked increase of L-Selectin expression by 30% on their surface 178 
when stimulated with WCS. This proved that three days of incubation are not enough to turn 179 
monocytes into macrophages without additional cytokine-stimulus. Furthermore it also represents the 180 
ability of WCS to greatly increase monocyte mobility by directly interfering with genetic expression of 181 
the host’s monocytes, as an increase in L-Selectin presentation is an indicator for a greater readiness 182 
to emigrate into tissue towards the site of infection. 183 
The monocyte-derived macrophages (MDMs) achieved after six days of incubation of monocytes 184 
showed minimal amounts of L-Selectin, which is an indicator for successful monocyte-maturation. The 185 
MDMs achieved in this manner were then incubated for 18 hours with WCS. Changes in morphology 186 
and CD163-expression were observed. We found a notable increase of internal complexity, 187 
represented by the SSC value in FACS and a tendency towards a slight decrease in size, represented 188 
by the FSC-value, when comparing activated with non-activated macrophages. The increase of 189 
internal complexity can be attributed towards an increased number of phagosomes. Whole cell 190 
sonicate consists of fragments of formerly whole cells that were treated with ultrasound, it is therefore 191 
to be expected that macrophages would increase their phagocytic activity in the presence of this 192 
antigen. The slight variation in size observed is not in keeping with any general knowledge about 193 
macrophages at the moment and may simply be attributed towards the small amount of individuals in 194 
this study. 195 
We also observed a marked increase of around 20% in CD163 on the surface of our monocyte-196 
derived macrophages after activating them with WCS when compared to non-activated MDMs. CD163 197 
belongs to the scavenger receptor cystine rich family type B and is a marker of alternatively activated 198 
M2 macrophages (23, 24). As described in the introduction, M2 macrophages are a diverse sub-199 
population that is predominantly occupied with wound healing and clearing of inflammation as well as 200 
tissue repair, but also participates in parasite clearing (25, 26). A recent study that established an in 201 
vitro model for granuloma formation in leprosy observed the same up-regulation of CD163 after 202 
activation with live M. leprae bacilli incubated with PBMCs (27). Recently it has also been 203 
hypothesized that CD163 functions as an alternative route of entry for M. leprae and that the observed 204 
up-regulation under influence of the bacteria is a mean of supporting the infection via facilitating the 205 
entry into host cells (28). These results were achieved with cells directly isolated from leprosy patients, 206 
observing 41.7% of isolated macrophages to be CD163 positive. Our observed up-regulation of 207 
21.1±5.6% may be due to our in vitro approach and activation through WCS as opposed to whole 208 
cells. 209 
It is of particular interest that, in the case of CD163 expression, cells under threat by M. leprae show 210 
an opposite reaction to cells under threat by M. tuberculosis. While in the latter case we find an 211 
expected decrease or stagnation in expression during active threat (15, 17, 18), M. leprae causes an 212 
increase. A strong hint on why this might be comes from Strebel et al. (18), as they found an up-213 
regulation of CD163 expression in Schistosomiasis-induced granuloma. The ability of Schistosoma-214 
species to circumvent and influence the immune-system is well-documented (18, 29, 30). It is possible 215 
that Mycobacterium leprae enhances M2-anti-inflammatory activity in order to escape immunological 216 
clearance. This is supported by findings that find exactly this enhancement in the case of patients 217 
suffering under lepromatous leprosy (31). 218 
In conclusion, we have observed that Mycobacterium leprae whole cell sonicate induces activating 219 
properties in monocytes and macrophages, up-regulating mobility in the former, represented by an 220 
increase of L-Selectin expression, and activating the M2 portion of the later, possibly as part of an 221 
evasion of the cellular immune answer. Future studies to support our hypothesis with greater numbers 222 
of individuals should be able to validate our results, which would help to develop an adequate in vitro 223 
macrophage activation model for leprosy as well as give intriguing implications on the activity of M2 224 
macrophages in bacterial disease. 225 
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Figure legends 329 
Figure 1: Reduction of CD62L in monocytes after six days: Expression of CD62L (APC) and CD14 330 
(FITC) on incubated monocytes on day zero (A – Q2) and after six days of incubation (B – Q2-1). The 331 
gating is different due to the measurements being taken at two different time points. It was, however, 332 
performed utilizing the appropriate isotype controls. 333 
Figure 2: Activation of monocytes with WCS after three days of incubation: Comparison of CD62-334 
L (APC, Q2) expression of day 3 monocytes without (A) and with (B, Q2) activation by WCS. 335 
Expression in B in this case is 34,8% higher. 336 
Figure 3: Change in size and internal complexity in macrophages caused by WCS: Size (FSC-337 
value) and internal complexity (SSC-value) in Macrophages without stimulation (A) and after 18 hours 338 
of incubation with WCS (B). 339 
Figure 4: CD163-expression in macrophages after activation with WCS: Non-activated (A, P2) and 340 
with WCS for 18 hours activated (B, P2) macrophages present different fluorescence after treatment 341 
with CD163-PE antibodies. Expression increases by 21.1%. 342 
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Abstract 
Background: Leprosy is one of the most neglected tropical diseases of the skin and the 
nerves caused by the intracellular pathogen Mycobacterium leprae. Natural killer cells, at 
early stages contribute towards establishment of the infection and subsequent adaptive 
immune responses. This study investigated the differential expression of natural killer cells 
transcriptome in paucibacillary and multibacillary leprosy patients. 
Methods: Peripheral blood mononuclear cells were extracted from ten leprosy patients (five 
paucibacillary and four multibacillary) and from three healthy, ethnically matched controls. 
The purified population of natural killer cells (>90%) were isolated from patients and controls. 
The mRNAs of natural killer cells were subsequently used for microarrays and gene 
expression in leprosy patients were compared to healthy controls. 
Results: The LCN2 and APOBEC3 genes were predominantly upregulated in paucibacillary 
patients. A comparison of paucibacillary and multibacillary patients with controls as a 
baseline revealed that multibacillary patients generally showed a higher transcription of 
genes associated with cell communication, such as SIRPG and various defensins. However, 
paucibacillary patients showed a down-regulation in comparison with healthy controls. 
Further, multibacillary patients also showed an upregulation in gene products involved in 
immunity. 
Conclusion: Differential transcriptome profile were observed between the investigated 
pauci- and multi-bacillary leprosy patients.  
 
Keywords: Leprosy, Mycobacterium leprae, natural killer cells 
Introduction 
Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Despite an 
effective antibiotic therapy to control the infection, number of new case detection and 
registered cases remain high in 130 countries worldwide [1]. The spectrum of leprosy 
presentation can be classified in between two extreme poles: paucibacillary (PB) and 
multibacillary (MB) [2]. While the paucibacillary (or tuberculoid) presentation is categorized 
as a successful immune response, owing to the little presence of bacilli and less than five 
lesions, the multibacillary (or lepromatous) form is considered a failure of immunity. 
According to the classical Ridley and Jopling scale based on the increasing severity of 
symptoms, the medical classification is further divided into tuberculoid (TT), borderline 
tuberculoid (BT), borderline borderline (BB), borderline lepromatous (BL), and lepromatous 
(LL). Generally, TT and BT individuals are considered part of the paucibacillary side of the 
spectrum, while BB, BL, and LL individuals are counted towards the multibacillary side. 
The clinical spectrum in leprosy is associated with host immune responses [2, 3], individual 
variability in host responses therefore can significantly influence the clinical outcome. The 
variety in immune response is caused directly by the ability of immunity to fight off M. leprae 
infection. The latter occurs most commonly because instead of cellular immunity, an 
antibody-based response is up-regulated. In addition, the bacterial load, which is the base of 
the multibacillary or paucibacillary diagnosis, is not strongly correlated with the severe 
lepromatous. Therefore, the gene expression profile of patients will provide a useful basic to 
understand their particular representation of the disease [4]. The failure of treatment can be 
traced back to immunogenetic properties of patients and is therefore a possible reason for 
the observed relapse during or shortly after treatment [5-7]. 
The primary targets of M. leprae are human macrophages and Schwann cells. Particularly, 
macrophages have been extensively studied in the context of leprosy due to their dual role 
as host cell and major player of innate immunity. Studies have shown that M. leprae was 
associated with massive modifying of infected macrophage functions such as inducing import 
of low density lipids or influencing the immune response, particularly via modulating 
inflammation [8] [9]. Accordingly, the effect of the bacteria on the transcriptome of 
macrophages and Schwann cells has been studied [10] [11]. Transcriptomic analysis was 
employed to study leprosy’s type I, a well-known phenomenon resulting in localized 
inflammation of skin and nerves after immunity in MB patients has been reinstated [12, 13]. 
Studies have also demonstrated the important role of natural killer (NK) cells in murine 
leprosy both in-vivo and in-vitro [14]. The macrophages heavily infected with M. 
lepraemurium were susceptible to be lysed by activated NK cells in-vitro, whereas control of 
monoclonal antibodies against NK cells enhanced susceptibility to mouse leprosy [14]. Also, 
treatment of BALB/c mice in the hind footpads with irradiated M. leprae led to a significant 
enhancement of natural killer activity [15]. 
Based on these promising findings and the important roles of both NK cells and 
macrophages in innate immunity, we aim to investigate the role of NK-cells in leprosy and 
their activation during M. leprae infection by transcriptome analysis. 
 
Materials and Methods 
Sampling and ethics 
The patient cohort consisted of individuals from the state of Andra Pradesh, India that had 
been diagnosed as either paucibacillary or multibacillary by the medical staff of the Blue 
Peter Public Health Research Centre (BPHRC). Diagnosis was made based upon clinical 
signs (less or more than five lesions, sensual impairment within the lesions, thickening of 
nerves) and histological presence of bacteria in skin slit smears. All of the patients had, 
without inflammatory episodes, completed multi-drug treatment according to WHO standards 
for their respective presentation of the disease 
(http://www.who.int/lep/mdt/regimens/en/index.html). 
Sampling occurred from February up until April 2013, including 24 patients altogether. As 
only 20 milliliters of venous blood could be used for NK cell and consecutive RNA isolation 
as per the ethical agreement, only seven samples of the highest quality and yield of RNA 
were chosen for microarray analysis. A summary of patient parameters is presented Table 1. 
Classification of leprosy was carried out according to Ridley Jopling. Paucibacillary (PB) 
patients were identified as having one to five well-defined lesions, none or only one 
thickened/tender nerve trunk, and they can be smear-negative. The classification as a 
multibacillary (MB) case was done as follows: Six or more lesions, more than one 
thickened/tender nerve trunk, a bacterial index greater than three, and smear positivity. We 
grouped patients based on their bacterial load rather than clinical representation, as the 
former is a quantifiable parameter. 
Three controls that were matched for ethnical background and came from the state of Andra 
Pradesh were included. All patients provided written informed consent before participating in 
this study. The standards of sampling followed the guidelines of the ethical committee of the 
BPHRC as specified in the context of the cooperation. 
PBMC processing 
PBMCs were isolated from fresh blood as previously described [16]. Briefly, 20 ml of fresh 
venous blood were taken utilizing 9 ml Monovette© ammonium-heparin-vacutainers by 
Sarstedt. The blood was mixed 1:1 with RPMI 1640 and the resulting solution was utilized in 
a Ficoll desnity gradient separation. After separation the PBMC-layer was taken off and 
washed twice in adequate medium (RPMI 1640 + 2% fetal bovine serum). The cells were 
transferred into growth medium (RPMI 1640 + 5% fetal bovine serum + 1% PenStrep + 1% 
L-Glutamine) at a concentration of 1.2x106 cells/ml and incubated in Corning® Costar® 24-
well plates for 18 hours. 
Cultured PBMCs were harvested from wells by vigorous pipetting. Harvested cells were 
treated with the Human untouched NK cell isolation kit by Miltenyi in order to achieve a purity 
of greater than 93%. The provided kit protocol was followed exactly. The achieved purity was 
tested by flow cytometry, identifying the NK cell population as CD56+CD3-. The utilized FACS 
buffer was made from 1x PBS plus 1% fetal bovine serum. 
After isolation, if a purity >93% had been achieved, RNA was isolated from the cells utilizing 
the RNEasy Mini Kit following the instructions of the manufacturer (Qiagen, Hilden, 
Germany).  
Microarray procedures 
Microarray procedures were performed in Hyderabad, India. RNA fidelity and concentration 
were estimated using the Bioanalyzer system (Agilent, Santa Clara, USA). The transcriptome 
analysis was carried out via the whole-genome cDNA-mediated Annealing, Selection, and 
Ligation (WG-DASL) assay (Illumina San Diego, USA). 
Statistical analysis 
Raw data was background corrected with standard Ilumina software. Hereafter all further 
processing and analysis was done with the software package R 2.13.0 (http://www.r-
project.org/). Two arrays were excluded from further analysis since they show a striking 
different correlation pattern to the other arrays detected by a correlation plot. This 
observation was further confirmed by hierarchical clustering using the average linkage 
method with Euclidian distance. 
The data was log2 transformed and normalized using quantile normalization as implemented 
in the software package Lumi. Sex chromosome specific genes (813 genes for the X 
chromosome, 102 genes for the Y chromosome) were excluded from further analysis as well 
as genes that have a non-significant detection call (P>0.01, 12206 genes) leaving 11794 
genes for further analysis. Differential expression was detected with the Limma package. 
Since we used only two arrays for each comparison none of the genes have a significant P 
value (FDR<0.05). Therefore we decided to focus on genes showing at least a fold change of 
3 between two conditions. 
 
Results 
Highly pure NK cell isolates could be achieved 
Out of 24 patient samples, sufficient amount of NK-cells at a purity of 93% or higher were 
isolated from 10. The increase in NK cell concentration, identifiable by presence of CD56 and 
absence of CD3 on the surface, is exemplified by the results of a patient isolation (Figure 1), 
where a purity of 96.4% was achieved. 
Finally, the RNA of seven out of ten samples with sufficient quantity and purity of NK cells 
was considered for microarray analysis (Table 1). The three remaining samples presented 
RNA of insufficient quality after concentrating it in preparation for hybridization onto the 
DASL chip and were therefore not included in further analysis. 
The cluster dendrogram of leprosy patients reveals three groups 
When comparing the expression profiles of the remaining patients (NK 2, 4-6, 8, and 11-12) 
with each other and with the healthy controls we found three groups emerging (Fig. 2): NK2 
and NK11 are both member of the paucibacillary (PB) group, while NK4 and NK6 both are 
multibacillary (MB) patients. NKK1 and NKK3 both belong to the control group. It is notable 
that we observed a number of outliers that couldn’t be included in any of the mentioned 
groups based on their expression, even including one of the controls. All of the outliers were 
excluded from further analysis. 
Comparison on single patient level reveals the importance of communication for 
natural killer cells in leprosy 
When comparing the remaining single patients with each other and with the single controls 
(Fig. 3), we found a number of genes up-regulated in infected individuals when compared to 
healthy controls (NKK samples). Of particular prominence were the genes for lipocalin 2 
(LCN2) and apolipoprotein B mRNA editing enzyme catalytic polypeptide 3 (APOBEC3), 
which both were less up-regulated, or even down-regulated, in multibacillary patients than in 
paucibacillary ones. 
We also found a number of Y- and X-chromosomally coded genes differentially expressed, 
such as protein kinase, Y-linked (PRKY) and kelch-like 4 (KLHL4) (not pictured). Those 
weren’t included into the results, though they were adequately expressed in different 
genders, with PRKY, for example, being only up-regulated in males. This serves as an 
additional quality control for the microarray data. 
The multibacillary patients differ from the control group 
Comparison of gene-expression in the MB group with the control group as a baseline 
revealed three clusters of interest in a heat map of flad-changes equal to or greater than 
log2(3) (Fig. 4).  
The first cluster is dominated by down-regulated gene-products that play a role in immunity 
(CD70, phospholipase A2, group IVC (cytosolic, calcium-independent) [PLA2G4C], and 
tumor necrosis factor receptor superfamily, member 9 [TNFRSF9]). 
The second, larger gene-cluster consists of strongly up-regulated genes. Many of the genes 
play no known role in immunity. However, this group also contains the NK-cell-activity 
specific gene-products of Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short 
(KIR2DS3) and CD93. 
The third and largest cluster of gene-products includes many proteins involved in general 
cell-cell-communication, like signal-regulatory protein gamma (SIRPG), or pro-platelet basic 
protein (chemokine (C-X-C motif) ligand 7) (PPBP). The gene-products in this cluster are 
moderately up-regulated when compared to the baseline. 
The paucibacillary patients present different clusters of gene-activity 
Observing figure 4 once more reveals that the gene expression of the patients belonging to 
the paucibacillary end of the spectrum is quite different from the multibacillary patients. Here 
too we observe three clusters for mostly the same genes as in the multibacillary cases, but 
the expressions are partially the diametrical opposite. 
The first cluster consists of four strongly up-regulated gene-products. They derive from 
NDUFA7 (NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex, 7), RMRP (RNA 
Component of Mitochondrial RNA Processing Endoribonuclease, also known as NME1), 
NME2 (NME/NM23 Nucleoside Diphosphate Kinase 2), and GDPD1 (Glycerophosphodiester 
Phosphodiesterase Domain Containing 1). In MB patients, they present an expression on par 
with the healthy controls. 
Cluster 2 consists almost exclusively of genes whose expression is only slightly or not at all 
up-regulated when compared with the healthy controls. It consists of the genes that form 
clusters one and two in the MB group. 
The last cluster in the PB group presents a mirror image to the third cluster in the MB group: 
The same genes that are moderately or strongly up-regulated in the former present a 
moderate or strong down-regulation in the latter. 
Quantitative differences between the MB and PB groups 
Table 2 presents the quantitative differences in the genes shown in the heat map figure 4, 
sorted by how far up- or down-regulated they are in comparison to the controls as well as 
how different the gene is in each group. CD70, for example, has a fold-change of -2.815 in 
the MB group and of 0.377 in the PB group, which is the greatest absolute distance in all of 
the displayed genes. We note that in the ten genes that differ the most in expression in the 
two groups we find a great number of genes with little to no known immunological activity, 
such as OXER1 or CCDC144A. 
Notable differential expression by a number of important genes 
Beyond the clusters presented in figure 4, a number of important genes were found to have 
notable differential expression when compared to healthy controls. The LY96 (also known as 
MD2) gene product, for example, was down-regulated by -1.85 in MB while being up-
regulated by 2.05 in PB cases. 
Both alpha 1 and beta defensin production was differential in MB and PB patients. DEFA1, 
encoding for alpha 1 defensin, was transcribed with fold-changes of 2.56 in MB patients and 
-3.17 in PB individuals. DEFA1B (alpha defensin 1B) presented comparable values: 2.37 in 
MB and -3.14 in PB cases. It is notable that DEFA3 presented a similar expression pattern, 
2.31 fold-change in MB and -2.98 in PB individuals. 
LILRA2’s expression was lower than in the controls for bot MB and PB patients, at -2.28 and 
-2.79, respectively. Production of IL8 was down-regulated by -1.6 in both MB and PB 
patients. The anti-microbial CTSG gene-product presented a fold-change of -2.08 in MB and 
of 2.46 in PB patients when compared to controls. 
 
Discussion 
It is important to note that a substantial number of our initial patient samples couldn’t be 
included in the further analysis, as their expression patterns were too different from the 
emerging groups. This may be due to the great variation in the immune answer that is typical 
in leprosy. It may also be an explanation why the sample NK12 actually groups with the 
control sample NKK2. NK12 may actually be the only individual that due to treatment 
reached expression levels that are comparable to a healthy control again, in this case NKK2. 
When observing the comparison of the remaining single patients amongst each other, we 
found a number of genes with varying importance in human immunity. One example is 
secreted phosphoprotein 1 (SPP1), which acts as a cytokine that up-regulates interferon 
gamma and interleukin 12 production, both important players in type 1 immunity. It is logical 
that such a cytokine would be up-regulated in a leprosy patient when compared to a healthy 
control. On the other hand we observed lipocalin 2 (LCN2) to be differentially expressed in 
the patients. While the paucibacillary patients showed a clear up-regulation of the protein 
production, the multibacillary cases were rather unchanged or even down-regulated. 
Lipocalin has been indicated in anti-bacterial activity [17-19], a reduced activity in MB 
patients, who are classified as having failed to mount a successful immune answer, is 
therefore remarkable. The same goes for the apparent down-regulation of apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide 3 (APOBEC3), which is normally associated 
with fighting off retroviral infections [20-22]. 
Comparing the patient groups with the control group as baseline revealed clusters of 
differentially expressed genes. As the remaining number of individuals (two for each group) 
was not high enough for statistically significant results, we opted to only include such genes 
that showed a fold-change equal to or greater than log3. Doing so and ordering the genes 
according to how much they differ from each other in the PB versus the MB group, we found 
that the gene that had the greatest difference in natural killer cells of leprosy patients is 
CD70. The gene product belongs to the tumor necrosis factor (TNF) ligand family and is a 
ligand for CD27 on T-cells, where the CD70/CD27 interaction is critical for the cell’s 
expansion and survival [23]. Furthermore, it has been proven that CD70 directly enhances 
the direct cytotoxic activity of natural killer and T-cells [24, 25]. The negative fold-change of -
2.8 in multibacillary cases is therefore of great interest. 
Opposed to this we found SIRPG (signal-regulatory protein gamma) with a slight up-
regulation (0.9) in the MB group and a strongly negative fold-change of -2.2 in the PB group. 
As the gene product of SIRPG is indicated in regulatory processes, especially in its 
interaction with CD47 [26], a strong variation in accordance to a differing representation of 
disease should prove to be a substantial change. 
Another gene product that is strongly indicated in regulatory processes and was also up-
regulated by a fold-change of 2.1 in the PB cohort of our study is RMRP (RNA component of 
mitochondrial RNA processing endoribonuclease), which has been proven to play a role in 
cell growth and division [27]. 
RMRP belongs to a cluster of four genes whose transcription was greatly up-regulated in PB 
patients, but on the same level as the baseline in MB individuals. The three additional genes 
were: NDUFA7 (NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex, 7), NME2 
(NME/NM23 Nucleoside Diphosphate Kinase 2), and GDPD1 (Glycerophosphodiester 
Phosphodiesterase Domain Containing 1). NDUFA7 is part of the electron transport chain in 
human mitochondria. NME2’s gene-product is integral in the production of nucleoside 
triphosphates and is known for playing a role in negatively regulating cell-proliferation and 
therefore hindering cancer development [28-30]. GDPD1 has only been poorly researched 
up to this point in time, though a study has identified the gene-product as a part of the 
general NK-cell membrane proteome [31]. Why any of the four genes in the strongly up-
regulated cluster of PB patients present themselves in this manner will have to be 
investigated further in future experiments. 
Also of interest is the small 0.6 up-regulation of PPBP (pro-platelet basic protein (chemokine 
(C-X-C motif) ligand 7) in the MB patients compared with the down-regulation of -1.7 in the 
PB cohort. Derivatives of PBP (platelet basic protein), such as PPBP, have demonstrated an 
anti-microbial activity in monocytes [32]. Also, the PPBP gene-product works as a chemo-
attractant for neutrophils [33]. It is therefore curious why there should be such a substantial 
down-regulation of a gene product with importance in innate immunity in the paucibacillary 
group. The paucibacillary pole of the leprosy spectrum is generally considered a 
representation of a working immune answer, for which an adequate innate immunity is 
paramount. 
Another gene whose transcription is down-regulated in the PB group is EMR4. The gene 
product is a member of the EGF-TM7 receptor gene family, though sequencing results 
indicates that it may be soluble instead of membrane-bound in humans. In this regard it 
becomes interesting as a possible mean of G-protein-mediated cellular signaling. This also 
makes the down-regulation of the FPR1 gene product in the PB group noteworthy. The 
negative fold-changes of Emr4 vs. Fpr1 (-1.9 vs. -1.8) are very similar, and Fpr1 is a member 
of the G-protein coupled receptor family 1. Fpr1 plays a role in natural killer cell-mediated 
cytolitic activity [34] and in anti-inflammatory activity [35]. 
KIR2DS3 is a member of the killer cell immunoglobulin-like receptor family and transfers 
activating signals into the natural killer cell. This makes the fold-change of roughly 1.9 
observed in the MB group interesting, especially as the gene also plays a role in other pro-
inflammatory diseases [36, 37].  
Another gene of interest due to its importance in immunity is tumor necrosis factor receptor 
superfamily, member 9 (TNFRSF9). The gene product is known for part-taking in the 
recognition of antigen presenting cells by T- and B-lymphocytes [38]. It has also been 
implicated in increasing dengue virus-mediated apoptosis in vitro [39]. Finally, CD93 may 
also be of interest, as it is known to be involved in cell-adhesion and phagocytosis [40, 41]. 
Observing expression outside of the clusters seen in figure 4 revealed a number of 
differentially expressed genes that are notable for their roles in host immunity (not pictured). 
Of particular interest is the expression of the DEFA1, DEFA1B, and DEFA3 gene products. 
All three genes code for variations of defensin alpha, an enzyme with anti-microbial 
properties predominantly produced in neutrophils and NK-cells [42, 43]. Our results 
presented a stronger expression in multibacillary cases and a weaker expression in 
paucibacillary cases when comparing them to healthy controls. Considering the anti-
microbial role of defensins this result is counter-intuitive. This may indicate an attempt of NK-
cells to compensate for the failure in effective host-defense in multibacillary cases. 
LY96, also known as MD2, codes for lymphocyte antigen 96. This enzyme interacts with toll-
like receptor 4 in the innate immune response, particularly to lipopolysaccharide [44, 45] and 
in inflammatory reactions [46]. As the gene-product was observed to be down-regulated in 
MB patients and up-regulated in PB patients, this may hint at a role in the defense against 
Mycobacterium leprae. 
Another gene-product we found to be down-regulated in MB cases and up-regulated in PB 
cases was that of CTSG. The gene codes for cathepsin G, an enzymatic protein belonging to 
the protease families mostly known for its involvement with neutrophilic cells. It conveys 
bactericidal activity and modulates inflammation [47]. In the context of our study it is notable 
that cathepsin G was found to contribute to lung-protective immunity against mycobacterial 
threat in a mouse model [48] as well as enhancing NK-cell cytotoxicity [49]. Given the 
involvement in immunity, the observations made in regards to MB and PB patients could 
indicate cathepsin G as a building block in mounting the host’s defense against leprosy. 
Finally, the LILRA2 gene product was down-regulated in both MB and PB cases. The gene 
encodes a leukocyte immunoglobulin-like receptor (subfamily A) which can suppress innate 
immune responses [50]. As innate immunity plays a big role in leprosy, it stands to reason 
that a receptor which reduces this activity would show decreased use in this disease. 
This is the first study that analyzes the whole transcriptome of natural killer cells in leprosy 
patients and compares the two opposing representations of the disease based on this 
context. Future studies will have to include greater patient cohorts, but the presented 
manuscript gives intriguing first hints as to why the disease can have such a great variety of 
representations in different humans and what role the natural killer cells may be playing in 
leprosy. 
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Tables: 
Table 1: Summary of included patients 
Sample Age Sex  Lepromatous or Tubeculoid Classification
on 
Steroids in 
the past
on MDT MDT duration
NK2 19 y/o f tuberculoid PB Yes 2 months
NK4 18 y/o m lepromatous MB Yes Yes ongoing
NK5 34 y/o m lepromatous MB Yes ongoing
NK6 43 y/o m lepromatous MB Yes ongoing
NK8 12 y/o m tuberculoid PB Yes 5m (child)
NK11 53 y/o f tuberculoid PB Yes ongoing
NK12 28 y/o f tuberculoid PB Yes ongoing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene MB PB
CD70 -2,815 0,377
HYDIN 2,183 -1,006
KRT72 0,747 -2,386
CCDC144A 2,343 -0,687
SIRPG 0,859 -2,155
KRT73 0,962 -1,928
TEX101 0,311 -2,568
SH3BGRL2 0,319 -2,347
NDUFA7 -0,406 2,258
OXER1 0,175 -2,348
C17orf97 2,181 -0,339
RASGRP4 0,468 -1,977
AURKB 2,020 -0,378
TDRD9 2,142 -0,189
RMRP -0,248 2,070
PPBP 0,559 -1,729
TMEM22 -1,871 0,409
SIGLECP3 1,861 -0,372
CHST13 0,442 -1,777
RPS23 1,780 -0,390
NME2 -0,324 1,827
LOC440348 1,885 -0,221
EMR4 0,163 -1,941
FPR1 0,249 -1,841
PACSIN1 0,324 -1,747
RNF17 1,734 -0,309
RTKN2 0,155 -1,882
NANOS1 -1,688 0,345
COL9A2 0,096 -1,880
ANO9 0,286 -1,679
KIR2DS3 1,855 -0,073
EMR4P 0,052 -1,859
GDPD1 -0,243 1,645
DYSF 1,775 -0,073
TNFRSF9 -1,664 0,078
MS4A6A 0,025 -1,656
CD93 1,591 -0,050
PLA2G4C -1,596 0,023
Difference in 
expression 
Table 2: Quantitative difference in expression of genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative difference in expression of genes with a fold-change greater or smaller than log2(3), 
respectively –log2(3), in either the paucibacillary (PB) or multibacillary (MB) group. 
 
 
Figures:  
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Figure 1: Example of success of natural killer (NK) cell isolation. NK cells are CD56-PE+ and CD3-
APC-. A: Before isolation. B: NK cell enrichment after isolation. C: Numerical representation of NK cell 
enrichment post isolation, Q1 is the representation of the CD56-PE+/CD3-APC- NK cell population and 
contains 96.4% of all cells in the suspension (up from ~15% before isolation, not pictured). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 2: Cluster dendrogram comparing the expression patterns of the patient and controls samples 
and grouping them accordingly. NK2 and NK11 are both paucibacillary, NK4 and NK6 are both 
multibacillary. NKK samples are healthy controls. Outliers: NK8 (PB), NK5 (MB), NK12 (PB), and 
NKK2 (healthy control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3: Comparison of differentially expressed genes in leprosy patients and healthy controls (NKK3 
and NKK11). NK2 and NK11 are paucibacillary patients, NK4 and NK6 are multibacillary.  
 
 
 
 
 
 
 
 
 
 PB       MB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Differentially expressed genes in the paucibacillary (PB) and multibacillary (MB) patient 
groups with healthy individuals as a baseline. All genes have a fold-change greater or smaller than 
log2(3), respectively –log2(3), in either the paucibacillary (PB) or multibacillary (MB) group. 
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